Podcasts about jardiance

In this episode, Adam kicks off the show with a surprisingly deep dive into the symbolism and social dynamics of sandwich-making, unpacking how something so simple says a lot about parenting, care, and culture. He then calls out Dr. Drew's notoriously bad bedside manners and rants about people who constantly unload their health issues on him. Later, Adam takes aim at a bizarre Jardiance commercial, tearing into its absurd list of side effects.In the news, Adam reacts to President Biden's first comments after a recent cancer diagnosis and his attempt at humor regarding his mental competency. He questions whether Democrats prioritize gun control over illegal immigration, shares his thoughts on the recent Boulder, Colorado terror attack, and breaks down how mass immigration can influence culture.Finally, Mission Impossible stuntman-turned-actor Stephen Oyoung joins Adam in the studio to talk about his journey into Hollywood, working alongside Tom Cruise, and the crazy world of action filmmaking. They also discuss Asian representation in media, Stephen's SoCal upbringing, his love of martial arts, and how Loveline helped shape his early years. Get it on.FOR MORE WITH ELISHA KRAUSS: INSTAGRAM: @elishakraussWEBSITE: elishakrauss.com JOURNAL: https://www.washingtonexaminer.com/author/elisha-krauss/FOR MORE WITH STEPHEN OYOUNGINSTAGRAM: @stephenoyoungTWITTER: @mrstephenoyoungThank you for supporting our sponsors:BetOnlineHomeChef.com/ADAMHomes.comoreillyauto.com/ADAMPluto.tvRosettastone.com/ADAMRuffGreens.com - Use promo code “Adam”SIMPLISAFE.COM/ADAMLIVE SHOWS: June 11 - Palm Springs, CAJune 13 - Salt Lake City, UT (2 shows)June 14 - Salt Lake City, UT (2 shows)June 19 - Las Vegas, NV (2 shows)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Shenanigans are really swell, stupid banter and a big story to tell (Side effects of Shenanigans include questioning the choices in your life). This week's show gives the sweet and talented Deanna Colón. This singer and entertainer has performed with and for Diana Ross and Patti Labelle, been on America's Got Talent & Masterchef, and been in commercials like Bad Bunny's Pepsi ad and the Jardiance jingle. We get to learn about who the “Bomb Chica” is and hear about her life.   We go off the rails as always and discuss Mike's signature dish, whether or not we'd go to space, and Scott tells a a cray story about one of the worst intro's in comedy show history.  Have a listen!

Episode 2623: Vinnie Tortorich and Chris Shaffer discuss news items that address junk food in the SNAP program, weight loss drug risks, and more. https://vinnietortorich.com/2025/03/weight-loss-drug-risks-episode-2623 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH ALL THE PODCAST EPISODES ON YOUTUBE -  Weight Loss Drug Risks Several states are trying to ban junk foods from being purchased from the SNAP program. (10:00) Each state defines junk food differently, but many define it as soda and candy. (13:30) The focus is trying to get people to purchase whole foods. The American Heart Association is pushing back against this move. (21:00) The various reasons the AHA gives are discussed and not all of them make sense. Vinnie and Chris review the list of companies and how much they contribute to the AHA each year. (28:15) One excuse claims the number of products is “just too hard” to list. The UK is now banning ads for junk food. (35:45) They discuss the drug Jardiance and the health disclaimers at the end of the ad. (38:00) Next in the discussion is Zepbound, which was used for sleep apnea, but is also marketed as a weight loss drug. (47:30) Vinnie emphasizes that going low-carb will give you none of the side effects that the medications will have. More News If you are interested in the NSNG® VIP group, closed for registration, but you can get on the wait list - Don't forget to check out Serena Scott Thomas on Days Of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it! Eat Happy Italian, Anna's next cookbook is available!  You can go to  You can order it from .  Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day!  Don't forget you can invest in Anna's Eat Happy Kitchen through StartEngine.  Details are at Eat Happy Kitchen.  There's a new NSNG® Foods promo code you can use! The promo code ONLY works on the NSNG® Foods website, NOT on Amazon. https://nsngfoods.com/   PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere:  Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere:  REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere:  FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: 

This week we are joined by Deanna Colon! Deanna is a singer, songwriter, actress, vocal coach, and chef. Deanna was a contestant on Season 8 of NBC's #1 rated show, “America's Got Talent”, making it to the live, quarter semifinal round at Radio City Music Hall in NYC. She was also the lead singer/dancer/actress for 2 years of BIG LOTS holiday commercials.Deanna has sung background vocals for many recording artists, including Nick Jonas, Celine Dion, Lea Michele, Justin Bieber, and Paula Abdul. On Season 10 of the FOX show Master Chef, Deanna won a coveted white apron from the judges and became a member of the elite Top 20. She also has garnered almost 300K followers on her Tik Tok cooking show “Fork My Life”. In 2023, Deanna was cast as the lead singer/actress/dancer in a huge national spot for pharmaceutical brand Jardiance. Make sure to check her out!In this episode, Deanna shares her multifaceted journey through the culinary and entertainment worlds. Deanna reflects on her upbringing in a family restaurant, the importance of travel and life experiences, and her discovery of a talent for singing that led her to a scholarship at Berklee College of Music. We share starstruck moments with music legends, reflect on the complexities of fame and personal safety, and discuss the reality of competition shows in the entertainment industry. Deanna discusses the importance of versatility in creative careers, her personal experiences with body image and acceptance, and the comfort food that brings her joy. Deanna also emphasizes the need for self-love and the challenges of being an outsider, while also highlighting her passion for cooking and connecting with others through food. Give this episode a listen!Recommendations From This Episode: WildCard KitchenMystic PizzaFollow Deanna Colon: @deannabombchica on Instagram and TikTokFollow Carly: @carlyjmontagFollow Emily: @thefunnywalshFollow the podcast: @aloneatlunchpodPlease rate and review the podcast! Spread the word! Tell your friends! Email us: aloneatlunch@gmail.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Ellen Kamhi talks with Dr. Swathi Varanasi-Diaz, an award-winning healthcare professional recognized for her trailblazing work at the forefront of personalized medicine and healthcare innovation. She earned her Doctor of Pharmacy from the Medical University of South Carolina and became the first pharmacist in the U.S. to complete a postdoctoral residency in integrative medicine and preventive health. Following this achievement, she co-founded the Integrative Health Pharmacy Residency Program. Her credentials also include a postdoctoral fellowship in biotech and nutrition from Cornell University.  Her research has been published in peer-reviewed academic journals and she has served as faculty and guest lecturer at numerous academic institutions. In 2023, was honored as one of 50 Most Influential Leaders in Pharmacy.  https://myosmd.com/

Welcome to the 45th episode of my drug pronunciation series! As we continue through the alphabet from A-Z, we're on the letter “E” for empagliflozin. Also check out episode 228 for ezetimibe and episode 134 for eszopiclone.   In this episode, I break down empagliflozin and Jardiance into syllables, tell you which syllables to emphasize, and share my sources.     The written pronunciations are helpful. They are below

Taxpayers are expected to save billions after the Biden administration inked deals with pharmaceutical companies to knock down the list prices for 10 of Medicare's costliest drugs. But how much older Americans can expect to save when they fill a prescription at their local pharmacy remains unclear, since the list cost isn't the final price people pay. After months of negotiations with manufacturers, list prices will be reduced by hundreds—in some cases, thousands—of dollars for 30-day supplies of popular drugs used by millions of people on Medicare, including blood thinners, diabetes drugs and blood cancer medications. The reductions, which range between 38% and 79%, take effect in 2026. Taxpayers spend more than $50 billion yearly on the 10 drugs, which include popular blood thinners Xarelto and Eliquis, and diabetes drugs Jardiance and Januvia. With the new prices, the administration says savings are expected to total $6 billion for taxpayers and $1.5 billion overall for some of the 67 million people who rely on Medicare. Details on those calculations, however, have not been released. And the White House said it could not provide an average cost-savings for individual Medicare enrollees who use the drugs. That's because there are a number of factors—from discounts to the coinsurance or copays for the person's Medicare drug plan—that determine the final price a person pays when they pick up their drugs at a pharmacy. The new drug prices are likely to most benefit people who use one of the negotiated drugs and are enrolled in a Medicare plan with coinsurance that leaves enrollees to pay a percentage of a drug's cost after they've met the deductible, said Tricia Neuman, an executive director at the health policy research nonprofit KFF. “It is hard to say, exactly, what any enrollee will save because it depends on their particular plan and their coinsurance,” Neuman said. “But for the many people who are in the plans that charge coinsurance, the lower negotiated price should translate directly to lower out-of-pocket costs.” This article was provided by The Associated Press.

Max gets ready for the big live show by doing some breathing exercises with Roger and talking through the show agenda on Wednesday, September 11th, 2024.LIVE SHOW IS TONIGHT AT 7PM AT CAVEAT NYC!!https://www.caveat.nyc/events/sports-talk-right-now-9-11-2024 Hosted on Acast. See acast.com/privacy for more information.

On today's MJ Morning Show: 'America's Cobbler' had a heart attack Buc-ees car wash Morons in the news Doctors warn of 'carnivore diet' (sounds to us like Atkins diet) A psych hospital isn't releasing patients? What is 'chroming'? 'The Babadook' MJ's October flight got changed... and more than he realized (it's fun to hear him get angry) Teacher put a 3-year-old in a headlock MJ has more rice cookers to give away Jardiance ad for Fester? You may unintentionally offend someone by wearing this... we took lots of calls Marketing firm admits to listening to people through their phones Trial date set for the Ketamine Queen Someone just signed on for a podcast... Okay, it was the 'Hawk Tuah' girl '1,000 lbs Sisters' sister arrested after being bitten by a camel... Um... what? Travis Kelce angry about fake contract Backlash against Capri Sun How much does Scottie Scheffler's caddy earn? Doctor tells patient she has a short life expectancy after seeing this Brian May of Queen lost use of his arm because of a stroke... but he's feeling much better, now... Rachael Ray fans concerned after her latest video Tip to law enforcement officers... don't leave your firearm in a Racetrac bathroom Intersection takeover arrests America's Cobbler, Jim McFarland, spoke to MJ Railing on Titanic isn't safe Fan knocked out at Tampa Bay Rays game by a home run ball Video of a Pepsi van barely getting across train tracks to avoid becoming scrap metal Car crashes through a Phoenix home, narrowly missing couple and their dogs

Can a simple lifestyle change reduce healthcare costs and improve patient outcomes without adding a cent to the budget? In this week's Crazy Medical Story on The Independent Physician's Blueprint, we explore a groundbreaking approach that could revolutionize the treatment of diabetes.In a recent study published by JAMA's Network Open Access, intermittent fasting outperformed standard medications like Jardiance and Metformin in controlling blood sugar levels. Coach JPMD shares his personal experience with intermittent fasting and its transformative effects on his energy and health. Discover how this underutilized strategy could be a game-changer for your patients and practice.Listen to learn how incorporating intermittent fasting into your medical practice can not only help manage diabetes more effectively but also reduce reliance on costly medications. This episode provides insights into a practical, evidence-based approach to improving patient outcomes without breaking the bank.Ready to rethink your approach to diabetes management? Tune in now and start implementing these life-changing strategies in your practice today!Reference: Guo L, Xi Y, Jin W, et al. A 5:2 Intermittent Fasting Meal Replacement Diet and Glycemic Control for Adults With Diabetes: The EARLY Randomized Clinical Trial. JAMA Netw Open. 2024;7(6):e2416786. doi:10.1001/jamanetworkopen.2024.16786Dr.Mindy Pelz - "Fast Like a Girl" https://drmindypelz.com/ Discover how medical graduates, junior doctors, and young physicians can navigate residency training programs, surgical residency, and locum tenens to increase income, enjoy independent practice, decrease stress, achieve financial freedom, and retire early, while maintaining patient satisfaction and exploring physician side gigs to tackle medical school loans.

DOWNLOAD THE FASTING TRANSFORMATION JOURNAL HERE! In today's episode of the "Fasting for Life" podcast, we discuss the use of intermittent fasting as a lifestyle intervention for managing and potentially reversing type 2 diabetes. We highlight a recent study comparing the outcomes of a 5:2 meal replacement fasting group to those on metformin or Jardiance, demonstrating superior results in the fasting group for glucose control, weight loss, and reduced side effects. The practical takeaway is emphasizing small, manageable lifestyle changes rather than extreme measures to achieve sustainable health improvements. We encourage listeners to consider integrating intermittent fasting and deliberate meal choices into their lives for long-term wellness benefits. FREE RESOURCE - DOWNLOAD THE NEW  BLUEPRINT TO FASTING FOR FAT LOSS! Learn how to RAMP UP into longer fasting windows! Gain insights into the non-weight loss benefits of fasting! Personalize your own fasting schedule and consistent FAT LOSS results! Get answers to what breaks a fast, how to break a fast, and tips and tricks to accelerate your fasting wins! THE BLUEPRINT TO FASTING FOR FAT LOSS DOWNLOAD Get your FREE BOX OF LMNT hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase here! Get 30% off a Keto-Mojo blood glucose and ketone monitor (discount shown at checkout)! Click here! Let's continue the conversation. Click the link below to JOIN the Fasting For Life Community, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! Fasting For Life Community - Join HERE New to the podcast and wondering where to start? Head to the website and download our  Fast Start Guide, 6 simple steps to put One Meal a Day Fasting (OMAD) into practice! Get our NEW sleep guide here! SLEEP GUIDE DIRECT DOWNLOAD If you enjoy the podcast, would you please tap on the stars below and consider leaving a short review on Apple Podcasts/iTunes? It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Research Links:

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: A new study looks at insulin needs in men vs women, updates on stem cell transplants and a new look at COVID 19 and T1D plus a fully implantable CGM is announced. We'll also tell you about a T1D athlete drafted to the MLB. Lots more in this week's episode, full transcipt below.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX Do men and women have different insulin requirements? A new study conducted across Europe says yes – women overall need less. Published in the Journal of Diabetes Science and Technology this looked at over 9,000 adults with type 1 diabetes using data from patients using the Diabeloop Generation 1 (DBLG1) hybrid closed-loop pump system. In this study, women needed 14-percent less insulin overall than men. These researchers say these findings have important implications for the practical management of insulin therapy and highlight the necessity of considering gender as a crucial factor in diabetes treatment. The treatment guidelines provided by American and European Diabetes Societies do not currently have gender-specific recommendations for insulin-weight ratios. The co-founder and Chief Scientific and Technical Officer for Diabeloop. “This study also highlights the capacity to discover new insights from big-data analysis of real-world data.” *Insulin Requirements According to Gender and Weight in a Population of 9036 Adult Persons With Type 1 Diabetes Using Closed-Loop Insulin Delivery, https://doi.org/10.1177/19322968241252366). https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/27419187/diabeloop-study-reveals-significative-gender-differences-in-insulin-requirements-for-type-1-diabetes-patients/   XX New drug therapy in those lucky diabetic mice boosted insulin-producing cells by 700% over three months, effectively reversing the disease. Scientists at Mount Sinai and City of Hope have been able to grow new beta cells in the body, in a matter of months. The therapy involved a combination of two drugs: one is harmine, a natural molecule found in certain plants, which works to inhibit an enzyme called DYRK1A found in beta cells. The second is a GLP1 receptor agonist. The latter is a class of diabetes drug that includes Ozempic, The researchers tested the therapy in mouse models of type 1 and 2 diabetes.. The signs of the disease quickly reversed, and stayed that way even a month after stopping the treatment.   The results are intriguing, but of course being an animal study means there's still much more work to be done before it could find clinical use. So far, harmine alone has recently undergone a phase 1 clinical trial in humans to test its safety and tolerability, while other DYRK1A inhibitors are planned for trials in humans next year. https://newatlas.com/medical/diabetes-reversing-drug-boosts-insulin-producing-cells/ XX Stem cell–derived beta-cell replacement therapy continues to show benefit in people with type 1 diabetes at a high risk for severe hypoglycemia. New info from Vertex shows that of a total 17 patients who received a full dose of their  investigational allogeneic stem cell–derived, fully differentiated pancreatic islet cell replacement therapy (VX-880), three, thus far, have achieved the primary study efficacy endpoint of elimination of severe hypoglycemic episodes with A1c < 7% at 1 year and the secondary endpoint of insulin independence. Others are on the same trajectory, Piotr Witkowski, MD, PhD, professor of surgery at The University of Chicago, Chicago, said at the recent American Diabetes Association (ADA) 84th Scientific Sessions. In his presentation, Witkowski also provided details about the deaths of two study participants that the company had announced in January 2024, neither of which were related to the VX-880 product. In fact, there have been no severe adverse events related to the product itself, with most due to either the infusion procedure or the immunosuppression. "These data highlight the curative potential of VX-880 in people living with type 1 diabetes and support further evaluation of VX-880 toward pivotal development," Witkowski said. For now, patients selected for the study are those who experience frequent severe hypoglycemia deemed to be a greater risk to the patient than that of immunosuppression. However, Ahn pointed out, "With VX-880, the obvious fly in the ointment is the need for immunosuppression which carries significant risk…There are multiple solutions being proposed, but we are still waiting for data as promising as the initial Vertex data is on that front." https://www.medscape.com/viewarticle/stem-cell-derived-islets-continue-show-benefit-t1d-2024a1000cx1 XX Still lots of COVID studies coming in about type 1. A German study suggests COVID 19 may speed up progression of existing but presymptomatic T1D in kids. These researchers had been screening and following children in an early presymptomatic stage of type 1 diabetes for several years. They noticed an increase in the numbers of Incidence of clinical type 1 diabetes nearly doubled after the pandemic started. "We know that the virus can infect the pancreatic islets so it could be causing damage or change in the beta cells that make insulin," said Ziegler when discussing possible mechanisms behind this association. "Second, there is generalized inflammation during the infection and there may be a stimulation of the immune response. Third, there could be metabolic stress from the infection that affects the beta cells that make insulin. To dive into this topic, youth were identified in the German Fr1da-screening program from 2015 to 2023. All patients had presymptomatic diabetes defined as persistent, confirmed positive results for two or more islet autoantibodies. Their progression was monitored at 3- to 6-month intervals. Clinical type 1 diabetes was defined according to American Diabetes Association   COVID infection was either self-reported via the family or identified with SARS-CoV-2 antibodies were confirmed in blood samples collected at study visits.   Vaccination against COVID-19 may be one way to protect presymptomatic type 1 diabetes youth from progression, Ziegler added. She said her group is currently testing whether COVID-19 vaccination can reduce new-onset, presymptomatic type 1 diabetes in a clinical trial  of children with genetic risk factors for the condition. https://www.medpagetoday.com/endocrinology/type1diabetes/111084 XX The FDA says no – for now - to Novo Nordisk's weekly insulin.  This has been approved in Canada and should be available there shortly. But the FDA says it wants more information related to the manufacturing process and the type 1 diabetes indication to complete the review. Novo said it does not expect to be able to fulfil the requests this year, and that it will work closely with the FDA regarding the next steps. The regulator's decision follows its outside panel's vote against the use of the weekly insulin icodec, in patients with type 1 diabetes due to risks of low blood sugar. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-novo-nordisks-weekly-insulin-2024-07-10/ XX A couple of weeks ago we spoke to the attorneys taking on CGM monitronig in schools. They've helped a family in Connecticut and set a precdent.  A child with autism and diabetes was not getting reasonable accommodations under the federal Americans with Disabilities Act in a public preschool program. I'll link up the press release from the DOJ but this family wasn't getting any support and it just wasn't safe. The lawyers here tell me the ruling and settlement is just going to help them going forward as they try to make schools complient with CGM as a reasonable  accomodatin. https://www.justice.gov/usao-ct/pr/aba-therapy-provider-make-changes-comply-americans-disabilities-act   XX Ozempic could lower the risk of dementia and a range of other mental problems compared with other existing treatments for patients with diabetes. What's more, researchers found that Ozempic cut nicotine dependence in those patients.   This study relied on medical records from more than 100,000 U.S. diabetes patients, including more than 20,000 who were prescribed semaglutide between December 2017 and May 2021. After a year, patients who took Ozempic had a 48% lower risk of developing dementia than those on Januvia. The risk in Ozempic patients was also 37% lower than those who took Glucotrol and 9% lower than those on Jardiance. Notably, previous research has determined that diabetes patients are at a greater risk of developing dementia. But the authors emphasized that the analysis is observational. The results need to be replicated in a controlled trial that assigns patients to randomly take Ozempic and the other drugs, according to Dr. Max Taquet, another Oxford clinical lecturer and senior study author. https://www.cnbc.com/2024/07/16/healthy-returns-ozempic-may-lower-dementia-risk-nicotine-use.html XX   Edgepark Commercial XX The Omnipod 5 with Dexcom G7 integration is now available through select pharmacies with full availability expected in the fall.   The System uses new Pods that are compatible with both Dexcom G6 and G7, but the prescription code will stay the same as the current Omnipod 5 Pods. This means the community will have similar insurance coverage and access to what they have with Omnipod 5 today.   If you're looking to start on Omnipod 5 and you're currently using Dexcom G7, your doctor will need to send a prescription for both the Omnipod 5 Intro Kit and Omnipod 5 Pods, compatible with Dexcom G6-G7, to ASPN Pharmacies.   You can learn more at https://www.omnipod.com/innovation/dexcom-g7.   If you are already using Omnipod 5, you will get the new Pods compatible with Dexcom G6 and G7 through your Pod refills. You do not need a new prescription. The week of July 29th, you will receive a free software update for the Omnipod 5 App to your Controller or compatible Android smartphone which is needed to use the System with Dexcom G7. Accept the update. We recommend you continue to use your current Omnipod 5 Pods and Dexcom G6 supplies until the new Pods compatible with Omnipod 5 with Dexcom G6-G7 are available at your preferred pharmacy.   We'll email our users when the new Pods are available in most pharmacies.   You can learn more at https://www.omnipod.com/innovation/new-compatible-devices   XX Big promises about long-term implantable blood glucose monitor from a company called Focus. They say they're partnering with Glucotrack to quote - transform how people with diabetes interact with their condition. They're not calling this a CGM – rather it's a CBGM, continuous blood glucose monitor because it will measure glucose levels in blood, not in interstital fluid like CGMs do. They company says this is a fully subdermal location, with no external wearable. In preclinical studies, the CBGM has a MARD of 4.7% at day 90. That is MUCH lower than CGMs on the market – Dexcom and Libre are in the low 8s right now. BUT.. it hasn't been fully tested in people yet. Human clinical trials are set to start later this year. https://www.drugdeliverybusiness.com/focus-collaborates-glucotrack-implantable-cbgm/ XX Big congrats to Jamie Ferrer (Chy-may Fer-rare) On Monday, Ferrer's dream was realized when the Twins selected the Florida State outfielder in the fourth round (No. 126 overall) during Day 2 of the MLB Draft. Minnesota vice president of amateur scouting Sean Johnson said the club had its eyes on Ferrer since high school. “Recently, I was in Orlando at a conference called, “Friends for Life with CWD [Children with Diabetes],” and we had an event that was a sports day. … Kids would come up to me and either them or their families would ask me how I dealt with this [or that],” Ferrer said. “And seeing their faces light up whenever I said I was diagnosed at three and I played college baseball. … You hear people tell you no and that you can't do this because you have Type 1 diabetes … So why not inspire as many people as I can?”   “I'm super proud of being a Type 1 athlete, and it's something that I'll never shy away from talking about or showing off my insulin pump because it's who I am and it's something that I've had to deal with my entire life.” https://www.mlb.com/news/jaime-ferrer-selected-no-126-overall-by-twins-in-2024-mlb-draft XX Join us again soon!

This episode has everything: curdled milk, tiny hats, the Tour de France, Big Gretch. And that's all before the break! In our SECOND segment, we explore our favorite topic of the week: ads.Move over Don Draper, because these two BBWs are coming through to serve up some of the best commercial moments you've ever heard. NOTHING helps ease the discomfort of humanity's agonizing downward spiral like a catchy little jingle! We learn about Lindy's legacy status in the advertising world and share some of the most iconic line reads from our favorite commercials (Robert Loggia???). Email us at deartextmeback@gmail.com to share what ads live rent-free in your brainestrone!Check out these (currently un-sponsored) faves!For amazing ice cream recipes, The Perfect Scoop by David LebovitzBrown Sugar-Bourbon Ice Cream by Bon AppetitGet into Cycling with us and watch the Tour de France on PeacockEnjoy Lindy's shoutout by THEE Big Gretch!And of course, go listen to ep where Lindy and Meagan wax poetic about the Jardiance commercial: Lindy and Meagan Corner the Husband Demographic⋆｡°✩⋆｡°✩⋆｡°✩⋆｡°If you like this episode and want us to keep making the show forever, please subscribe to our Patreon. This podcast will always be free, but we need your help to produce it -- and if you support our Patreon, you'll get all kinds of goodies in addition to the show itself! Learn more about the different tiers and rewards here: https://www.patreon.com/TextMeBackPodAlso! Please keep in touch with us! You can text OR CALL us at the Best Friend Party Phone: (703) 829-0003.We're on Instagram at @textmebackpod!Full videos of our episodes are on YouTube at @textlindyandmeaganbackYou can email us at deartextmeback@gmail.com!WE WANT TO HEAR FROM YOU SO BAD!⋆｡°✩⋆｡°✩⋆｡°✩⋆｡°TEXT ME BACK is a production of Lindy West and Meagan Hatcher-Mays, proud members of the BFF Network. Our senior producer is Meagan Hatcher-Mays. Our other senior producer is Lindy West. Our show is supported by COPILOT Collective and produced by Alli Slice.Our music is by Chief Ahamefule J. Oluo. Diana Bowen is our video and creative advisor. Our digital strategist is Chance Nichols.You can also follow the podcast on Instagram and TikTok @textmebackpod. And for even more bestie content, follow Lindy and Meagan on Instagram at @thelindywest and @importantmeagan!Special thanks as always to our perfect angels: Jeannie Yandel, Brandi Fullwood, and Isolde Raftery.⋆｡°✩⋆｡°✩⋆｡°✩⋆｡°See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What will we pay for the next groundbreaking drug? In episode 4 of our 5-episode series, “Insight Unpacked: American Healthcare and Its Web of Misaligned Incentives,” we explore the trade-off at the heart of pharmaceutical innovation. On this episode, we hear from Kellogg faculty members Amanda Starc and Craig Garthwaite, as well as Boston University School of Law's Kevin Outterson.  Visit the episode page for supplementary materials. 

In hour two of A Numbers Game, Gill Alexander and Kelley Bydlon are joined by Chris Fallica to talk about today's Euro 2024 and Copa America matches, Deanna Colon joins to talk about her Jardiance commercial success and more, and Jason Weingarten joins to give out his best bets for today's MLB slate.See omnystudio.com/listener for privacy information.

In hour two of A Numbers Game, Gill Alexander and Kelley Bydlon are joined by Chris Fallica to talk about today's Euro 2024 and Copa America matches, Deanna Colon joins to talk about her Jardiance commercial success and more, and Jason Weingarten joins to give out his best bets for today's MLB slate.See omnystudio.com/listener for privacy information.

This week we are proud to report that we have a husband listener! Welcome, buddy! And what a time to be a new listener and/or a husband, because in this episode Lindy and Meagan are doing the Lord's work: ranking dragons. We're talking about Smaug. We're talking about Puff. We're talking about…the other ones.BUT THEN, as if that wasn't enough, Lindy and Meagan bravely breach a topic few have dedicated so much air time to. It's a little something with a big story to tell, it's the must-have accessory for your high A1C, it's an ear worm even mightier than the one in RFK Jr.'s brain. It's the Jardiance jingle, and in case you were wondering: yes, we play it in its entirety.If YOU are a husband who listens to the show, we want to hear from your wife! Let her know how much you love the show, and have her text or call us at the Best Friend Party Phone: (703) 829-0003.⋆｡°✩⋆｡°✩⋆｡°✩⋆｡°If you like this episode and want us to keep making the show forever, please subscribe to our Patreon. This podcast will always be free, but we need your help to produce it -- and if you support our Patreon, you'll get all kinds of goodies in addition to the show itself! Learn more about the different tiers and rewards here: https://www.patreon.com/TextMeBackPodAlso! Please keep in touch with us! You can text OR CALL us at the Best Friend Party Phone: (703) 829-0003.We're on Instagram at @textmebackpod!Full videos of our episodes are on YouTube at @textlindyandmeaganbackYou can email us at deartextmeback@gmail.com!WE WANT TO HEAR FROM YOU SO BAD!⋆｡°✩⋆｡°✩⋆｡°✩⋆｡°TEXT ME BACK is a production of Lindy West and Meagan Hatcher-Mays, proud members of the BFF Network. Our senior producer is Meagan Hatcher-Mays. Our other senior producer is Lindy West. Our show is supported by COPILOT Collective and produced by Alli Slice.Our music is by Chief Ahamefule J. Oluo. Diana Bowen is our video and creative advisor. Our digital strategist is Chance Nichols.You can also follow the podcast on Instagram and TikTok @textmebackpod. And for even more bestie content, follow Lindy and Meagan on Instagram at @thelindywest and @importantmeagan!Special thanks as always to our perfect angels: Jeannie Yandel, Brandi Fullwood, and Isolde Raftery.⋆｡°✩⋆｡°✩⋆｡°✩⋆｡°See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Question: Does anyone care about Pikeman? Follow-up question: Does anyone understand anything related to Pikeman? For Gia and Keisha, the answers are No and Really No. In fact, Gia wouldn't mind if coffee took center stage (she wants the tv to emit coffee-like smells, but she's out in the blazing sun with her weedwhacker all day, so...you know). And Keisha would take a Jardiance commercial over another discussion about Pikeman any day. Wait--really? No, no, no. But it's neck and neck. Meanwhile, Ava is messing with Natalia, and that might be okay. Please, though, someone, take Sonny to a real doctor. Or a good nurse. Get this guy sorted out,  #mauricebenard  #kellythiebaud #rogerhowarth #maurawest #steveburton #delirious #tshirtgiveaway #barshampoo #daydrinkingwithsethmeyers #hillstreetblues #kinshriner #saveava #nicholaschavez #savediane #stonewallkitchen #hallandoates #superstore #freaksandgeeks #waitingonafriend #memyselfi #freefallin #alanarkin #whosgonnarideyourwildhorses #maneater #whippingpost #colonoscopy #takethenap #alleymills #billylibby #chickadee #fortgorgeous #robertgossett #daydrinkingwithsethandlizzo #marcuscoloma #useastaplegun #riptwitch #ripepiphany #ripsonyaeddy  #waywardchickadee #barshampoo #ripmiffy #lovedogs #justinebateman #brookeshields #neilgaiman #dnice #cq #deborahcox #malcolmjamalwarner #lume #ripjacklynzeman #jasonmomoa #adambelanoff #thecloser #majorcrimes #wings #murphybrown #thecosbyshow #pinkalicious #ripbillymiller #ripmatthewperry #riptylerchristopher #ripandrebraugher #ripjohnnywactor

Garry discusses a recent interview with one of the cast members of the Jardiance commercial. Plus, the former home of Paul Reubens is for sale.

"SGLT2-Hemmer", so nett man eine Gruppe von Medikamenten, die durch ihre Wirkung an der Niere die Diabetes-Einstellung verbessern. Die können mehr - über ihre Wirkung bei Herzschwäche und wie sie mithelfen, Herz-Kreislauf-Todesfälle zu verhindern.

This week on the show, Ford is all by himself and he has a bone to pick with AT&T and Jardiance, plus Shirley Phelps-Roper is on the program to talk Succession's Brian Cox, OJ Simpson, He Gets Us and so much more! Don't forget to hit the subscribe button! Help support the show by subscribing! Joining our Patreon.com/radioford or hooking us up on Venmo @radioford or Cash App @radioford If you want to buy the BRAND NEW sexy flexy fit that Ford shows off on this show, bigradioford@gmail.com on PayPal or @radioford on Venmo! Help support the show and spread the love! We have the following sizes: S/M, L/XL, XL/XXL and the quantities are limited! ALSO! The brand new snapback trucker mesh hat!

Resources for the Community:https://www.ivimhealth.com/weightloss/ Telehealth for weight management________________________________________________________________________joinfridays.comUe code PLUS10 to save________________________________________________________________________https://joinweightcare.com/products/s...https://joinweightcare.com/products/t...The Plus SideZ subscribers  get $300 off monthly Semaglutide and Tirzepatide programs with coupon code - PLUSSIDEZ.  And $100 off our 3-month Semaglutide and Tirzepatide programs with coupon code - PLUSSIDEZ3.________________________________________________________________________In this episode, we chat with a community member, Deanna "BombChica" Colon about her struggles with obesity and working with a trainer that had their own obesity bias. She lent her voice for the Jardiance commercial and faced much online bullying. We cover the traumas of being obese in a “slim” world and connect over mutual obesity experiences from living in a larger body. We also chatted with Dr Weiss, a board certified obesity specialist that co founded Fridays, an obesity medicine tele-health company. The team covers obesity bias in medicine, the future of obesity treatment, and predict changes in practice used to determine health (such as BMI). ________________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF________________________________________________________________________________________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide #GLP #GLP1 #Obesity#ObesitySupport the showKim Carlos @DMFKimonMounjaro on TikTokJernine Trott @TheeJernine on TikTokKat Carter @KatCarter7 on TikTokLydia Roberts @UnapologeticallyNapster on TikTok

In past episodes of this podcast, we've discussed disparities in healthcare. We've looked at evidence that shows members of historically underserved communities who are living with MS can face a more severe disease course. We've looked at studies that have shown some members of these racial and ethnic minority groups don't do as well on disease-modifying therapies, and their MS progresses more quickly. It's often been speculated that the reason behind these disparities is based on genetics -- that members of minority communities who are living with MS are genetically predisposed to experiencing a more severe disease course.  My guest in this episode is Dr. Annette Langer-Gould, and Dr. Langer-Gould comes armed with evidence that points to a completely different set of answers for the cause of racial and ethnic disparities in MS disease severity and progression. We're also sharing registration details for the National MS Society's MS Activist Rally on April 25th! We'll tell you about an inverse vaccine that prevents the mouse model of MS (and we'll explain what an inverse vaccine is!) You'll find out where you can find the just-released video progress report from the International Progressive MS Alliance. We'll explain just-published results from an analysis that shows why anti-diabetic and weight-loss drugs like Ozempic, Jardiance, and Trulicity may be repurposed as MS therapies. And we're sharing study results with both good news and not so great news when it comes to being diagnosed and treated for MS in a timely manner. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: We're exploring the reason that members of underserved minority populations who are living with MS often experience a more severe disease course  :22 The MS Activist Rally is happening on 4/25!  1:28 An inverse vaccine prevents the mouse model of MS  3:49 The International Progressive MS Alliance has released their 2024 progress report  6:13 Can weight-loss drugs be repurposed as MS therapies?  7:33 A study shows that getting diagnosed and treated for MS is dependent upon your country's healthcare system  10:26 Dr. Annette Langer-Gould has a sobering answer as to why some members of minority communities who are living with MS experience a more severe disease course  14:48 Share this episode  31:31 Have you downloaded the free RealTalk MS app?  31:51 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/346 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com REGISTER for the MS Activist Rally https://events.zoom.us/ev/Ame2jWSuHmriG94cyQmlWHr45mgnzxkDv8oMZRGsrS3ZxiSj5rro~Anqb3dHg3ewiz4KNHn2Ena4bgli_WXlza_zcygZN3GinnleB6rO15OCzGQ VIDEO: International Progressive MS Alliance 2024 Progress Report https://www.youtube.com/watch?v=4ojRaLp_J1w STUDY: Exploring the Association Between Weight Loss-Inducing Medications and Multiple Sclerosis: Insights from the FDA Adverse Event Reporting System Database https://journals.sagepub.com/doi/10.1177/17562864241241383 STUDY: Disease-Modifying Therapy Initiation Patterns in Multiple Sclerosis in Three Large Populations https://journals.sagepub.com/doi/10.1177/17562864241233044 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 346 Guest: Dr. Annette Langer-Gould Privacy Policy  

Resources for the Community:https://www.ivimhealth.com/weightloss/ Telehealth for weight management________________________________________________________________________joinfridays.comUe code PLUS10 to save________________________________________________________________________https://joinweightcare.com/products/s...https://joinweightcare.com/products/t...The Plus SideZ subscribers  get $300 off monthly Semaglutide and Tirzepatide programs with coupon code - PLUSSIDEZ.  And $100 off our 3-month Semaglutide and Tirzepatide programs with coupon code - PLUSSIDEZ3.________________________________________________________________________In this episode, we chat with a community member, Deanna "BombChica" Colon about her struggles with obesity and working with a trainer that had their own obesity bias. She lent her voice for the Jardiance commercial and faced much online bullying. We cover the traumas of being obese in a “slim” world and connect over mutual obesity experiences from living in a larger body. We also chatted with Dr Weiss, a board certified obesity specialist that co founded Fridays, an obesity medicine tele-health company. The team covers obesity bias in medicine, the future of obesity treatment, and predict changes in practice used to determine health (such as BMI). ________________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF________________________________________________________________________________________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide #GLP #GLP1 #Obesity #ObesitySupport the showKim Carlos @DMFKimonMounjaro on TikTokJernine Trott @TheeJernine on TikTokKat Carter @KatCarter7 on TikTokLydia Roberts @UnapologeticallyNapster on TikTok

While the tradition of wine is still important to how we connect with customers, the way that we communicate has changed. David Avrin, President of The Customer Experience Advantage explains why brands must have an omnichannel approach to their customer communication. Identify which channels are most valuable to your business by defining your core audience. Then find out what they watch, what they read, and where they recreate. Use these insights to harness the technology that your customers use whether its snail mail or TikTok. David reminds us that there is no shame in not being comfortable with technology but there is no excuse to not work with a technology native who does understand the platforms that best reach your audience. Resources:         82: Getting to Know Your Wine Customer 85: It‘s Time for New Wine Sales Strategies 98: Selling Wine in Non-Traditional Channels 161: Use Storytelling to Sell More Wine David Avrin Website David Avrin Books David Avrin LinkedIn David Avrin YouTube Social Media: Facebook | Instagram Vineyard Team Programs: Juan Nevarez Memorial Scholarship - Donate SIP Certified – Show your care for the people and planet   Sustainable Ag Expo – The premiere winegrowing event of the year Sustainable Winegrowing On-Demand (Western SARE) – Learn at your own pace Vineyard Team – Become a Member Get More Subscribe wherever you listen so you never miss an episode on the latest science and research with the Sustainable Winegrowing Podcast. Since 1994, Vineyard Team has been your resource for workshops and field demonstrations, research, and events dedicated to the stewardship of our natural resources. Learn more at www.vineyardteam.org.   Transcript Craig Macmillan  0:00  Our guest today is David Avrin. He is president of the customer experience advantage. Today we're going to talk about a little bit about the business side, and how that applies sustainability in the wine industry. Thanks for being on the podcast.   David Arvin  0:14  Thank you very much for having me.   Craig Macmillan  0:16  Now, we've talked about wineries vineyards, but their businesses. In your mind, what are some of the important things that winery and vineyard owners might think about in terms of making their companies sustainable into the future?   David Arvin  0:29  Yeah, it's interesting, because I think the industry certainly has been around for a very long time. And when it goes back to Biblical times, and there's there's certain ways that vineyard owners, those who are in the business suppliers, and others, this is how we do business, this is how it's done. But what's interesting is for the rest of us, who are the wine consumers, our lives have changed. And it's actually for everybody, right? How we connect, and share and grow our own businesses, and our changing expectations for access and immediacy, and flexibility, all of that has changed. So I think part of future proofing your business is striking that balance between the traditions, that, that go into making a great vintage wine, and how we interact and how we engage as consumers in the b2b side with distributors and others as well. So many of those mechanisms have changed. So I think what's really important is for people to be very clear on the technologies that are expected, and the ones that facilitate great communication in great relationships. I saw a study the other day, and the gist of it said that, that companies today are expected to deploy technology that allows their customers to do business with them, not from home, from anywhere, at any time, I don't expect that I can get my hair cut at four o'clock in the morning, but I expect that I can make an appointment to do so or cancel that appointment. So I think it's a very unique industry, because the traditions and what is tried and true and effective are so important to maintain, so important to pass along from generation to generation, but how we connect and communicate and deliver those services, those products, all of that has changed. We need to stay on the front end of that.   Craig Macmillan  2:09  One of the attractions of wine, I think, in my experience with customers, is this traditional aspect this is this is something mystical about it. And how do we maintain that kind of magical quality to a product, when we need to engage with the customer in more electronic ways or more distant ways, and maybe without as much touch?   David Arvin  2:31  I think it's just the business part of it, that it requires that kind of an expeditious, ease of use kind of a methodology are really virtual wine tastings unless you're actually tasting wine in different locations and connecting electronically.   Craig Macmillan  2:46  And that's happened.   David Arvin  2:47  Yeah, yeah, absolutely. We did it during COVID. We had so many double dates with my wife and some other couples and stuff, and just opportunity just over a glass of wine and some dinner, to just hang out with each other. It's one of things we learned during the pandemic that was possible. But I think when I've talked about the technology, I think it really is purely just how do we do business, my, my mantra, my new book is all about how to be how to become ridiculously easy to do business with. And so I think fortunately for the industry, I think the traditions still hold true. I think in person, wine tastings and wine enjoys and pairings at restaurants, I think a lot of that will pretty much stay the same. I think it's we're always want to stay on the forefront of that. But it's the the communication, the distribution, the marketing. There are so many new amazing mechanisms now to reach our target market, which is shifting, of course, we can talk about that. But it's using the mechanisms that they use. And so we can be traditional, but we certainly don't want to be seen as stodgy or antiquated, or old school. And so I think there's there's a really wonderful balance that in the terminus is fully intentional, because there's so much that balance comes into this industry. But I think in terms of our communication and our marketing and our in person enjoyment. I think that part's all very important.   Craig Macmillan  4:07  He mentioned the generational change. And that's an issue for the wine business, the generation that really brought us to where we are today, their children, and then possibly their grandchildren are coming of age, they're coming of age. And the question is whether that love of the wine product has been passed on generationally or not. One thing that I learned from looking at some of your other talks and stuff was, it's about and you mentioned it was the ease of connection and the ease of doing business and convenience.   David Arvin  4:40  I think on the business side is that I think there's a great opportunity for the industry to become not just present and relevant but preferable to a new generation as well. It's not like there isn't a long history with wine. As I said, going back to Biblical times. They have survived so well over the years. But what's different is each generation How we communicate, and how we connect and reach out, all of that has changed. I think wine is uniquely positioned to capitalize on that new as long as these generations come to fruition that Gen X, the Gen Y, the Gen Z, and all of them as well, because I think there's a natural progression of maturity in the individual. It's like there's a space, I think, between the parties. And I remember when party was a noun, now it is a verb. And then of course, the the more traditional and stodgy. I think wine is uniquely placed in there. And so while the young people are, they're going to play drinking games at 18, to 23, 24, you know, playing quarters with beer, the opportunity when when it's time to grow up, we grab a glass of wine, and we connect together. So you might have party and the stodgy I think the middle is social. And I think wine has a phenomenal opportunity right now to be positioned as the social drinker, we're not drinking to get drunk. We're not drinking to be to be sophisticated in in our smoking jackets with a high ball and of whiskey. But I think wine lends itself phenomenally to visuals, as well. And so I think if you're going to compare it to industries that have survived and thrived in that transition, I think coffee is probably the best. I mean, we grew up our parents, you go down, look for 15 cents, get a cup of joe. Well, now everybody's enjoying coffee, it's become more profitable, it's become more prevalent, because they've looked at a couple of things. One is the social aspect. And Starbucks had a big role to play in how we look at that experiential thing. But it's also a grab and go kind of an item, being able to recognize how easy do we do that and take that to the office. And that industry has done it very well. No, wine, of course, is something different. We don't necessarily take to the office, but the visuals of people who have come of age socializing, and not just drunk at a frat party, I think there's wonderful opportunities in terms of our marketing to say, when you're when you finally grown up, this is how we connect, this is how we socialize. And the other part of it, I think, is the packaging. And this part has been really fun for us because we are of the mind of so many, that when we get invited to a gathering, we always come with a bottle of wine. What's interesting is talking to others that one of the primary drivers. And this really takes us back to like 50 60, 70s was the emergence of clever and attractive packaging. It's less important today in other industries. But I think it's more important in the wine industry. The clever names, the clever packaging, so many people I've talked to say, I just thought this bottle looks so cool. And that's the one that they bring, right. That's not the bottle we tend to open up we like to display because there's so much creativity in that the elegant yesteryear of wine was a very elegant, labelled today. They're whimsical, they're fanciful, they're, they're tongue in cheek, and everything from the 99 crimes that you can scan and get a little story about them to Menage a Trios, which, which, you know, gives people a little bit of a smile when you realize the the inference, I think is such an exciting industry right now. I think the biggest population bubble in history is coming of age, and the perfect target. And then we look at the social how they communicate as well. Whether it's Instagram, or tick tock, for others, as well short form social short form video, it lends itself so well, two people connecting and gathering and enjoying life and sharing a bottle of wine.   Craig Macmillan  8:23  I'm a dinosaur, I just turned 55. And I work sometimes in the tasting room, the winery where I work now Niner Wine Estates, as time went on, it became very clear that I was not able to communicate with my coworkers, because they were talking about Instagram, they were using Twitter, they were Venmoing everything like I couldn't even be involved in social gatherings without getting Venmo on my phone. It's a here's 20 bucks and like, I don't want that. No, I wanted my Venmo account. Yeah, so one of them actually offered to become my social media consultant. And that is still continued to this day. So how can we make it easy for the consumer to interact with winery, if the consumer is not either tech savvy or in my case doesn't want to be tech savvy.   David Arvin  9:11  The term that you're going to hear so often which is which is omni channel. And omni channel means no matter how they want to communicate with you give them that opportunity. I mean, you talk about Venmo, for example, and I speak to audiences around the world, I write books on all of this. And one of the things I talk about in the new book that I'm writing right now, which is called ridiculously easy to do business with one of the chapters is be ridiculously easy to pay, you know, somebody wants to pay you through Venmo Okay, and this is scary for people with very traditional businesses. And I'm like, oh my god, somebody's trying to give you money, say yes. As you had recognized sometimes it takes a younger person who is a technology native who is immersed in all of this to help you translate and help you implement. There is no shame in not being comfortable with some of the new social media platforms or mechanisms. There is no excuse to not work with somebody who is and just because it might be a little bit scary. And for I mean, if you're old, I'm ancient, my kids run circles around me are all of our kids where we've got a Brady Bunch, they're all sort of 20 to 29. And I've got two of them who do digital marketing and digital media for a living. I wrote books if you can, if you're watching the video behind me, I wrote books, and I couldn't keep up today. But what we do is we surround ourselves, we outsource we, we hand off to people who are comfortable with those mechanisms. So when I talked before up omni channel, we're all going to have people, we're going to have customers from 21 to 85 or above, they want to communicate with you differently, they want to access the product differently, some might be able to do sort of online video introductions, a tour of the winery, some things that look very experiential, and some are very, very comfortable using the app and doing things online ordering. And there's another segment that needs to talk to a person for for those in business, those who are listening to this podcast, you don't have to be all things to all people. But you have to be very clear of who your audience is, and who your future audience is. And make sure that you have the processes in place for them to reach you by phone, by text message. However, that might be an even if it's just the b2b aspect of your business and dealing with vendors and others as well. No matter how they want to communicate, try and make that available. We look at the lifetime value of our customers, both on the consumer side and also on the distribution side. being ridiculously easy to do business with is a competitive advantage today. And all of this is with a recognition that you have to be good at what you do, right? This isn't in lieu of a quality product, don't take your eye off the ball. But what's different today, what's different post pandemic is that our mechanisms for how do we communicate or pay or order or reorder have got to be simple and streamlined. And then when we look at the audience is how do they where are they getting their information if you want to really target those, those 21 to 30 year olds posting clever, engaging intent and enticing videos on Tik Tok or Instagram, it's not fluff, it's business. If that's where they get their information, you need to be there. You need to be there effective.   Craig Macmillan  12:11  And that raises another question. I think it's tough for a lot of businesses just in general, how do you keep up on all this stuff? As there's new applications? There's new channels, there's new preferences, that's another one Pay Pal was the thing. So yeah, Pay Pal? I'm cool PayPal Venmo I'd never heard of it until somebody demanded that as a payment. If I'm the general manager of a business or if I'm an executive, how do I stay on top of this?   David Arvin  12:34  Um, first of all, is the recognition you don't have to do everything. Because it is overwhelming. It's 100%. You don't have to be on every social media platform. You don't have to take every form of payment. You don't have to take Bitcoin, I would advise against it. But it doesn't absolve you of the responsibility to be a student of business be a lifelong learner of business. And there's no shortage of content available online. That tells you here the the the hottest trends, how do millennials or Gen Z prefer to communicate what is their greatest influence into what they buy? When and why just read I mean, there's videos on on online every day, part of my responsibility to my clients and my audiences that I serve is I need to be very, very current. There was somebody who had booked me to to keynote a conference and that's my my primary business as a keynote speaker. And it was six months away. And they asked if I would send they were finalizing things if I would send my slide deck. And I said, I'm happy to send my slide deck but understand it's not what I'm going to present to you in six months, because things will change between now and that whether you have a second generation who's moving up within your business, make sure that you have people of all ages in the room as you discuss strategy. I think to answer your question, just be a student of this there is no shortage go on YouTube is the second biggest search engine in the world only second to Google, and it's owned by Google. But YouTube is a wonderful way to have just looking at stories and news clips and others about what are the latest trends. How are they predominantly buying? Where does Gen Z get most of their information? Right? I saw some of the day was fascinating that Disney was suffering in a significant way just because the youngest of our people are getting most of their videos and content online now on YouTube and others and it's in lieu of that it's not like they did anything wrong. Bed Bath and Beyond goes bankrupt not because they did a bad job. It's that we had changed and how we buy and how we connect we just get it delivered to our house through Amazon or something else. So I for me, I think it's it's a it's an exciting thing. It's a positive thing to be a constant learner, stay up to date and relieve yourself of the pressure to do everything. Just look who is my core audience? What do they watch? What do they read? Where do they recreate and congregate and dine and connect and are we there? And are we there in a way that is is not just present and not overly salesy. Persuasive and social and big the big rule in social media is don't sell share.   Craig Macmillan  15:04  I was reading something this morning, which reminded me of a topic that we had talked about internally in our winery. And that is the the idea of story. You just mentioned that storytelling. We also know that attention spans are short. And we know that a lot of us technology is set up for no more than a minute, two minutes, three minutes, how do I tell a really compelling story in a short amount of time? there's   David Arvin  15:28  Well,  two ways to do it. One is a story, a traditional story. And that might be through an article, it might be through a longer form video, it tells us a situation or something about a Thanksgiving dinner, and something that emotional happens. And you see that on the table. Most of story today, in terms of short form, video format, is literally very short. It can be a 22nd, Instagram reel, with pictures and pictures and pictures and lots of lots of music. I think the best example, if you think and look at how pharmaceutical companies are doing their commercials today, for Jardiance, or whatever those might be, whether it's a musical number, how often you see seniors at a farmers market, or at a kid's birthday party, but they're showing them connecting, and being being social, and family. And they just put these scenarios, you don't really know what the whole story is. But it puts it within the context as opposed to somebody holding up the product. And talking about the product. It's what do we want people to feel and I think that's the greatest opportunity for wine today, when looking at Gen Y millennials, or Gen Z is is is showing them in the in the kinds of situations that makes sense. It's laughter It's friendship, it's it's connecting, but it's also post fraternity party, it's post red solo cup, I could see a great ad campaign when you're ready to graduate from the red solo cup to a nice glass of Chardonnay, right? But that doesn't mean that somebody's 60 years old, it can be young and sophisticated. And the romance and all of that I think the stories can be told in short form, through the visuals, you know, and the music and all the things that and once again, here's here's a great thing about about YouTube, you can go on YouTube and search, how do you use YouTube? And you'll see a million videos, how do you create Instagram reels that capture the attention or look for others within your industry don't copy but emulate you know, which are the ones that get engagement and why I think it's an exciting thing to become a student of this. And I've learned so much from my kids who are no longer kids. My oldest daughter works for the number one social media channel on the planet. And they post videos and they get between 40 and 50 million views on their videos in the first 24 hours. Wow. And so what I'm learning from them is astonishing. And did I mention I wrote books on this?   Craig Macmillan  15:29  You said you've got one out right now what is that?   David Arvin  17:22  Yeah, well, but my new subject, and it's not really new. But I realized about seven or eight years ago because I talked about marketing and branding for most of my career, what are the what are the words we use that best describe and differentiate what we do in the marketplace. And I came to the recognition probably seven or eight years ago that we had changed in such a substantial way because of social proof that what we say about ourselves, is not unimportant, but it's not nearly important, today's what other people say about us. And it's Yelp and TripAdvisor and rotten tomatoes, and Glassdoor and of course all of the your own social media sites. So I might that's what led to my research would lead to my book, why customers leave and how to win them back is one of the points of frustration, friction in the process, unnecessary delays and, and lack of convenience for certain things. My whole business changed. And so all of my work and my research and my speaking and my books are around the central theme that in a marketplace where everybody's good. The winners are the ones who are ridiculously easy to do business with.   Craig Macmillan  18:56  I think you just answered the question, but what is the one thing you'd recommend?   David Arvin  19:00  There's two aspects Well, once the business aspect, and the other one is the marketing. So I think in terms of internal process, you have to be able to replicate what we're seeing in a broader marketplace. You have to be able to reach somebody, if somebody's yelling into the phone agent, real person real person, you're doing something wrong, right doesn't mean we can staff 24 hours but we're learning we can learn from Uber and Amazon and Domino's and others as well in terms of how do they use the mobile technology to make it super easy to reach someone to ask a question to reorder, make sure you have an off ramp so they can talk to a real person. That's the ridiculously easy walk your customers journey. Are there too many steps? How long is your contracts, we're seeing companies reducing their contracts and things that are really relevant and important. Be easy to work with your distributors and your vendors and others as well. And then of course on the marketing side is just recognize who not only your buyers are today, but your future buyers. Beware they are speaking language that's persuasive, authentic for them as well. And I think this this is one in industry and I speak to industries that are really struggling. I think the sky's the limit for the wine industry.   Craig Macmillan  20:05  So where can people find out more about you?   David Arvin  20:08  You find me online. My name is David Averin AVRIN, I'm on all social media on some of them. It's the real David AVRIN. That's a whole cat fish for another day. But you can look me up at Davidavrin.com or just google music videos as well. And as we had said, Before I speak and I consult. I love talking business. I'm a fan of business and I'm very optimistic about where we are post pandemic.   Craig Macmillan  20:32  Fantastic. Hey, we gotta go. Thanks for being on the podcast. David. Our guest today was David Avrin, president of the customer experience advantage   Nearly perfect transcription by https://otter.ai

Leor is an endocrinology fellow and he sees patients with diabetes, among other metabolic diseases associated with insulin resistance. He thinks the mainstream approach to dietary recommendations can actually serve as a barrier to improvement for some patients. Timestamps: 00:00 Trailer. 00:50 Introduction. 05:28 Insulin resistance medical and lifestyle challenges. 09:32 Insulin resistance linked to cardiovascular disease risk. 12:26 USDA promoting processed foods, overeating. 14:53 Individualized approach for managing hypoglycemia risk. 18:44 Improved health through carnivore diet and mindful eating. 19:57 Hesitant about recommending red meat in diets. 25:03 Research studies on carnivore diet and diabetes. 26:32 Thyroid affects cholesterol levels; replacement therapy. 28:59 Carnivore diet may help reduce autoimmune symptoms. 32:27 Jardiance trial shows reduced cardiovascular events, increased LDL. 36:11 Encouraging healthy eating over medications for weight loss. 38:42 Does eating stimulate heart rate like drug? 41:41 Plant-based approach. 45:43 Dietary advice from dietitians. 47:58 Reducing medications. 50:25 Where to find Leor.   See open positions at Revero: https://jobs.lever.co/Revero/ Join Carnivore Diet for a free 30 day trial: https://carnivore.diet/join/ Carnivore Shirts: https://merch.carnivore.diet Subscribe to our Newsletter: https://carnivore.diet/subscribe/ . ‪#revero #shawnbaker #Carnivorediet #MeatHeals #HealthCreation   #humanfood #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree  ‪

The Mousedebaters talk Disney Lyrics

Garry shares his thoughts on the new Jardiance commercial. Plus, explorers are sharing news that they may have found Amelia Earhart's missing plane.

"Frau Doktor, was macht denn das Zeug in meinem Körper GENAU?" Ich liebe diese Frage! Hier erkläre ich die Familie der "SGLT2-Hemmer", dazu gehören Jardiance (Empaglifozin) - Forxiga (Dapaglifozn) - Canaglifozin, Ertuglifozin

Dave Dameshek (ESPN and Extra Points podcast) joins Jason and Randy to discuss the NFL's Wild Card Weekend, Steelers football, Jardiance commercials, the Dallas Cowboys failing again, Bellichick's future, Tony Dungy trying to bring Jesus to Taylor Swift, Jimmy Butler's music career, Russell Westbrook challenging fans to fight, James Dolan allegedly trafficking a masseuse to Harvey Weinstein, and Jerry Jones (Chris Cox) calls in to talk about the Cowboys future, and so much more!

Deanna Colon...She the perky singing/dancing woman in the highly ubiquitous commercial for a diabetes drug called "Jardiance." The trolls of social media have emerged from under their bridges and have piled on to fat shame this woman criticizing dancing, her singing and, of course, her obesity proving again that fat shaming remains in full force as the least legal prejudice, --- Send in a voice message: https://podcasters.spotify.com/pod/show/peter-tauriello/message

What is Type 2 diabetes?  Body not able to control sugars – sugars become  in body high  Basically due to the pancreas wearing out over time not producing enough insulin or insulin becoming ineffective.  We are seeing more cases in younger people especially Māori and Pacific.     How big a problem is it and what harm to the body does it cause?  Thought to be approximately 300,000 in NZ living with type 2 diabetes.  Health system cost 2.1 billion year – 0.67% GDP!  Individual cost: increased rates renal failure, heart disease, blindness, leg amputation, if not controlled.     What are the new medications?  Diet, exercise and  weight reduction  central to treatment. Medications are needed such as metformin and insulin.    Now available two new medications:  Jardiance daily tablet: causes us to ‘pee' sugar out of the body when we urinate.  Trulicity- weekly injection: mimics a hormone that means we feel full and eat less and absorb sugar within body and can lose weight.     Why are they important?  Gives more treatment options in addition to metformin and insulin.    Major differences don't just lower sugar in body: also protect kidney from damage , and reduce chances of heart disease, and weight reduction: first time ever!  In Higher doses Trulicity the weekly injection:  has been used overseas for weight reduction ( Ozempic, Saxena New Zealand – not funded here) – has been in news  Lead  to worldwide  shortages at times that have affected New Zealand.     What should we do?  Important over age of 40 have regular blood sugar tests to see if developing problem.  Need to review regularly with GP and nurse: diet, exercise in combination with medication is important.  LISTEN ABOVESee omnystudio.com/listener for privacy information.

In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from September 18, 2023 – September 22, 2023.  Please check back every Monday morning so that you can stay up to date.  Check out our free downloads at nascentmc.com: Implementing AMA Style – 8 Things to Get Right in Your Next Project Needs Assessments – 7 Essentials for Getting Funded Working With Your Medical Writer – 8 Ways to Get the Most out of Them See more details summaries and links to prescribing information at nascentmc.com/podcast Here are the highlights: Jardiance (empagliflozin) for CKD  The FDA has approved Jardiance, an SGLT2 inhibitor, for patients with end-stage kidney disease, speciifically to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. The approval is based on the EMPA-KIDNEY phase 3 trial, demonstrating a significant reduction in kidney disease progression and cardiovascular death compared to a placebo.  Welireg (belzutifan) for Advanced Renal Cell Carcinoma The FDA granted Priority Review for Merck's Welireg for advanced renal cell carcinoma post other treatments. Welireg, a HIF-2α inhibitor, is being evaluated in the LITESPARK-005 trial, where it was compared with everolimus for advanced RCC treatment post PD-1/L1 or VEGF-TKI therapies. Tevimbra (tislelizumab) for Esophageal Squamous Cell Carcinoma The FDA is reviewing an application for Tevimbra for treating advanced or metastatic esophageal squamous cell carcinoma. Supported by the phase 3 RATIONALE 306 study, the drug improves overall survival rates when combined with chemotherapy in these patients. Neffy Epinephrine Nasal Spray The FDA rejected the approval of Neffy, a needle-free nasal spray for allergic reactions. Despite a positive Advisory Committee vote, the FDA demands further testing. ARS Pharmaceuticals plans to re-submit its application and appeal the decision in 2024.  Intro and outro music Garden Of Love by Pk jazz Collective

The federal government announced it has selected the first 10 drugs it will negotiate for lower prices with pharmaceutical firms. The Centers for Medicare and Medicaid Services selected the drugs, all of which are covered under Medicare Part D. The 10 drugs — Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog — accounted for .5 billion of total costs for Medicare's Part D program from June 2022 to May 2023. Medicare plans to use the cost savings to place a ,000 limit on enrollees' of out-of-pocket expenditures for drugs starting in 2026. But it could delay innovation...Article Link

Mark Twain once said, “Never put off till tomorrow, what you can do the day after tomorrow.” As an antidote to that Ralph welcomes Professor Piers Steel, author of “The Procrastination Equation: How to Stop Putting Things Off and Start Getting Stuff Done.” Plus, Ralph urges listeners to sign up for The Capitol Hill Citizen Association, another way to organize citizens to put pressure on the branch of our government where things must get done, the United States Congress.  Dr. Piers Steel is one of the world's leading researchers and speakers on the science of motivation and procrastination. Dr. Steel is a professor in the Organizational Behaviour and Human Resources area at the University of Calgary, and is the Brookfield Research Chair at the Haskayne School of Business. He is the author of The Procrastination Equation: How to Stop Putting Things Off and Start Getting Stuff Done.The root of procrastination is impulsiveness. Impulsiveness is valuing the now more than the later… We're designed to value the now. And this was really adaptive for a long time. It's not a bad trait. It's just that we've designed a world to take advantage of every little flaw that we have in our decision-making system.Dr. Piers SteelYou have to deal with yourself as an imperfect, flawed creature and deal with the reality of that. We're not robotic angels of perfection. We have limitations. And when I actually act within my limitations, I get stuff done.Dr. Piers SteelWe're superstars of self-control in the animal kingdom. We're able to hunt and kill most anything because we're willing to actually put in the delay of gratification. That's really what makes us great. But we're still not ready for things that are happening even a year off, much less five or ten.Dr. Piers SteelMore people will listen to what we just said about becoming part of the Capitol Hill Citizen Association and say to themselves, “I'm going to get around to doing that,” than the actual number of people who do it in a prompt period of time. So it would be very good to listen to Professor Steel's suggestions and read his book, because we cannot afford procrastinatory citizens. We have a procrastinatory Congress, and the citizens have got to get them to anticipate, to foresee, to forestall so many of the omnicidal urgencies that are coming at our country and other countries around the world.Ralph NaderTo become a member of the Capitol Hill Citizen Association, click here.In Case You Haven't Heard with Francesco DeSantis1. On August 28th, 20 groups – ranging from Left-wing anti-war organizations like Veterans for Peace to Right-leaning government transparency groups like R Street Institute – sent a letter to the Chairs and Ranking Members of the House and Senate Armed Services Committees demanding they maintain Rep. Jamaal Bowman's Cost of War amendment in the final National Defense Authorization Act. This provision “requires public disclosure about the cost of the U.S.' overseas military footprint and gives the American people greater transparency on military spending.” Hopefully, the left-right consensus on this issue is enough to maintain this amendment.2. In other Pentagon news, the Intercept reports that Rep. Matt Gaetz, Republican of Florida, has introduced an amendment demanding the Pentagon “collect information on trainees who overthrow their governments,” following the recent spate of coups in Africa. Gaetz told the Intercept “The Department of Defense, up until this point, has not kept data regarding the people they train who participate in coups to overthrow democratically elected — or any — governments.” This could become a flashpoint as Congress prepares to consider the 2024 NDAA when it returns from recess in September.3. As expected, tensions are running high in Guatemala following the upset victory of anti-corruption crusader Bernardo Arevalo. Opponents of Arevalo had urged the country's electoral tribunal to suspend his Semilla party on dubious legal grounds, which the tribunal resisted hewing to the letter of the law which dictated such actions could not be taken during the electoral process. After the election however, the party was officially suspended. Now, Reuters reports that suspension has been revoked, following a mass mobilization of Arevalo supporters in Guatemala City. It seems unlikely however that Arevalo's political opponents will accept his victory without a fight.4. In a dangerous, anti-free speech move, the Attorney General of Georgia has filed RICO indictments against 42 individuals involved with the Stop Cop City protest movement, the Atlanta Community Press Collective reports. This is the latest in a long line of attempts to quash opposition to the project, which has so far included trumped up domestic terrorism charges and arrests for handing out flyers.  5. Bloomberg reports that President Biden and Brazilian President Lula will jointly call for new worker protections at the upcoming General Assembly of the United Nations. While the article notes the two leaders have been “at odds” over China and Russia, they align on the topic of labor unionization. The two presidents have found common ground before, such as on the issue of climate change.6. Visual Effects workers at Disney have filed for unionization, per the Hollywood Reporter. Approximately 80% of VFX staff have already signed union cards, demanding an NLRB election and representation by the International Alliance of Theatrical Stage Employees or IATSE. This comes on the heels of a similar announcement by VFX workers at Marvel, a Disney subsidiary. In recent years. studios have increasingly relied on VFX workers in a rather blatant attempt to cut costs, as VFX workers have generally been non-union.7. At long last, the Department of Health and Human Services has announced the first ten drugs that will be subject to Mecicare negotiations to bring down prices. These are: Eliquis, Jardiance, Xarelto, Januvia Farxiga, Entresto, Enbrel, Imbruvica, Stelara and – crucially – several brands of insulin. HHS noted that “These selected drugs accounted for $50.5 billion in total [Medicare] Part D gross covered prescription drug costs, or about 20%, of total Part D gross between June 1, 2022 and May 31, 2023.”8. The Washington Post reports Acting Labor Secretary Julie Su has proposed new overtime rules intended to “extend overtime pay to an additional 3.6 million salaried white-collar workers in the United States.” According to current rules, workers are exempt from overtime if they make over $35,568 per year; the new rules would extend to workers making under $55,000 annually. If implemented, this would mean a whole new class of workers would be eligible for time-and-a-half pay if they work more than 40 hours per week.9. Per Republic Report: “The U.S. Department of Education announced…that it is cancelling $72 million in student loan obligations for more than 2,300 former students who attended for-profit Ashford University between 2009 and 2020.” Yet, even now the shady operators behind Ashford may still be able to squeeze money out of the taxpayers via a convoluted buyout by the University of Arizona Global Campus. Still, this marks a significant victory in a legal battle that has raged for over a decade, with Senator Tom Harkin of Iowa calling Ashford a “complete scam” all the way back in 2011.10. Finally, in more debt related news, the Philadelphia Inquirer has published a piece detailing how the nonprofit RIP Medical Debt was able to purchase – and forgive – over $1.6 million in medical debt. As the piece explains “When hospitals or physician groups have delinquent debts they have little chance of collecting on, they'll typically go to what's called the secondary market and sell their portfolios for pennies on the dollar.” It was on this secondary market that RIP Medical Debt was able to buy $1.6 million worth of debt for just $17,000. In celebration, “30 proud, self-described gutter-pagan, mostly queer dirtbags in their early 30s,” gathered for a ritual burning of an oversized medical bill. Someone chanted “debt is hell” and the crowd responded “let it burn.” Get full access to Ralph Nader Radio Hour at www.ralphnaderradiohour.com/subscribe

The little pill with the big story to tell.

Politisches Risiko und hoch im Kurs Wer meine Podcasts Börsenminute und GELDMEISTERIN schon länger verfolgt, weiß, dass ich Pharmaaktien für mein Langfristportfolio als eine wichtige Säule favorisiere und das tue ich auch weiterhin. Nur: durch die letzten starken Anstiege vor allem beim skandinavischen Shootingstar Novo Nordisk (Stichwort Diabetesmedikamente, die als Abnehmpille Furore machen) bin ich dabei, mein Pharma-Portfolio zu Rebalancieren, sprich einen Teil der Kursraketen zu verkaufen, um den Gesundheitstitel-Anteil und so mein Klumpenrisiko wieder zu reduzieren. Oder mir maximal die jüngsten Rohrkrepierer wie Roche zumindest genauer anzuschauen. Denn Risiko-behaftet sind Gesundheitstitel in jedem Fall und da denke ich nicht einmal an etwaige Nebenwirkungen, die in der Vergangenheit schon des Öfteren zu sündteuren Klagen geführt haben. Nein, es sind die Bewertungen, die ich teilweise nicht mehr gesund finde. Eli Lilly zum Beispiel hat in den letzten fünf Jahren um 430 Prozent zugelegt. Das Kurs-Gewinn-Verhältnis liegt bei knapp 56. Soll heißen, ich muss - aus heutiger Sicht wohlgemerkt - 56 Jahre warten, bis ich den Preis für die Aktie hereinverdient habe. Das dauert mir zu lange, auch wenn ich ihnen viel Gewinnsteigerungspotenzial noch zutraue. Man sollte keinesfalls das politische Risiko der Branche unterschätzen. Joe Biden hat gerade zehn Medikamente auf seiner Watchlist, die seinen „Inflation Reduction Act“ konterkarieren. Hier wird gerade mit Bristol-Myers, Johnson & Johnsohn, Merck, Novo Nordisk, Boehringer Ingelheim, Novartis, Amgen & Co gefeilscht, welche Preise das staatliche Gesundheitssystem künftig nur noch für die Arznei bereit ist zu bezahlen und das ist nicht unerheblich. Zum einen, schreibt die Financial Times, droht ihnen eine Besteuerung von 65 bis 95 Prozent, zum anderen ein Ausschluss aus dem Gesundheitsprogramm Medicare, was tragisch wäre, da es teilweise zu 50 Prozent ihre Umsätze in den USA sichert. Die konkreten Medikamente, deren Preise für Biden´s Geschmack zu hoch sind, findet ihr hier im Beipackzettel zu dieser Börsenminute: • Eliquis von Bristol-Myers Squibb (NYSE:BMY); • Jardiance von Boehringer Ingelheim; • Xarelto von Johnson & Johnson (NYSE:JNJ); • Januvia von Merck (NYSE:MRK); • Farxiga von AstraZeneca (NASDAQ:AZN); • Entresto von Novartis (NYSE:NVS); • Enbrel von Amgen (NASDAQ:AMGN); • Imbruvica von AbbVie (NYSE:ABBV); • Stelara von Janssen (im Besitz von JNJ); • Fiasp, Fiasp FlexTouch, Fiasp PenFill, NovoLog, NovoLog FlexPen, NovoLog PenFill von Novo Nordisk (NYSE:NVO). Rechtshinweis: Dies ist die Meinunung der Autorin und keine Anlageempfehlung. Was ihr daraus macht ist Eure Sache, Julia Kistner übernimmt hierfür keine Haftung. #Börse #investment #Pharmatitel #Inflationreductionact #Aktien #podcast Foto: Unsplash

  Unpacking the first Medicare drug price negotiation list, the NAIFA, FSP, and Life Happens merger, Apple's Wonderlust Event and more!    Follow Us on Social! Ritter on Facebook, https://www.facebook.com/RitterIM Instagram, https://www.instagram.com/ritter.insurance.marketing/ LinkedIn, https://www.linkedin.com/company/ritter-insurance-marketing TikTok, https://www.tiktok.com/@ritterim Twitter, https://twitter.com/RitterIM and Youtube, https://www.youtube.com/user/RitterInsurance Sarah on LinkedIn, https://www.linkedin.com/in/sjrueppel/ Instagram, https://www.instagram.com/thesarahjrueppel/ and Threads, https://www.threads.net/@thesarahjrueppel  Tina on LinkedIn, https://www.linkedin.com/in/tina-lamoreux-6384b7199/   Resources: 4 Effective Techniques for Closing Insurance Sales: https://agentsurvivalguide.podbean.com/e/4-effective-techniques-for-closing-insurance-sales/ Best Practices for Conducting an Interview featuring Dylan Cook: https://agentsurvivalguide.podbean.com/e/best-practices-for-conducting-an-interview-featuring-dylan-cook/ CMS Announces First 10 Drugs for Medicare Drug Price Negotiation: https://www.ritterim.com/blog/cms-announces-first-10-drugs-for-medicare-drug-price-negotiation/ How to Overcome Common Insurance Sales Objections ft. Dan Ford: https://agentsurvivalguide.podbean.com/e/how-to-overcome-common-insurance-sales-objections-ft-dan-ford/ Understanding the C-SNP Product & Opportunity ft. Ben Miller (Zing Health): https://agentsurvivalguide.podbean.com/e/understanding-the-c-snp-product-opportunity-ft-ben-miller-zing-health/   References: 5 actual clues in Apple's iPhone 15 Wonderlust event invite: https://www.macworld.com/article/2046187/wonderlust-event-invite-clues-colors-apple-watch-iphone-15-airpods.html Apple announces the iPhone 15 launch event: https://www.theverge.com/2023/8/29/23819494/apple-september-event-iphone-15-pro-watch-ultra-date Apple Events: https://www.apple.com/apple-events/ Blood thinners, diabetes meds among first 10 drugs for US price negotiations: https://www.reuters.com/business/healthcare-pharmaceuticals/us-name-first-10-drugs-medicare-price-negotiation-2023-08-29/ Eliquis, Jardiance, Xarelto headline CMS' price negotiation list: https://www.fiercehealthcare.com/payers/eliquis-jardiance-xarelto-headline-cms-price-negotiated-drug-list Factsheet: Medicare Drug Price Negotiation Program: https://www.cms.gov/files/document/fact-sheet-medicare-selected-drug-negotiation-list-ipay-2026.pdf HHS Selects the First Drugs for Medicare Drug Price Negotiation: https://www.hhs.gov/about/news/2023/08/29/hhs-selects-the-first-drugs-for-medicare-drug-price-negotiation.html Medicare Price Negotiation: Ten Drugs That Made the List, and Ten That Should Have: https://prospect.org/health/2023-08-30-medicare-price-negotiation-first-ten-drugs/ NAIFA, FSP and Life Happens announce plan to unite: https://insurancenewsnet.com/innarticle/naifa-fsp-and-life-happens-announce-plan-to-unite Strike Force Five: https://open.spotify.com/show/3YnUJC2alA6I1F2V7CdDa2?si=781e5bb1354e4406 The Late-Night Dudes Are Doing a Daytime Pod: https://www.vulture.com/article/late-night-hosts-podcast-strike-force-five.html

Florida Gov and GOP 2024 also-ran Ron DeSantis looks to lead in wake of violence and major hurricane | Former SC Gov and UN Ambassador under President Trump, Nikki Haley is having a moment, kind of | President Biden names first 10 drugs subject to negotations with Medicare | 60th anniversary of the March on WashingtonSong playsIntro by hostWelcome to Heartland Pod Wednesday!Support this show and all the work in the Heartland POD universe by going to heartlandpod.com and clicking the link for Patreon, or go to Patreon.com/HeartlandPod to sign up. Membership starts at $1/month, with even more extra shows and special access at the higher levels. No matter the level you choose, your membership helps us create these independent shows as we work together to change the conversation.Alright! Let's get into it: Hurricane in Florida / Shooting in FloridaPOLITICO: DeSantis knows how to handle a hurricane. The racist shooting poses a bigger dilemma.A racially-motivated Jacksonville tragedy, couple with a looming storm, pose big tests for the governor.Florida Gov. Ron DeSantis, center and his wife Casey, right, bow their heads during a prayer.Florida Gov. Ron DeSantis (center) and his wife Casey bow their heads during a prayer at a vigil for the victims of Saturday's mass shooting on Sunday, Aug. 27, 2023, in Jacksonville. | John Raoux/AP PhotoBy KIMBERLY LEONARD08/28/2023 04:14 PM EDTUpdated: 08/28/2023 05:12 PM EDTMIAMI — Florida Gov. Ron DeSantis' handling of back-to-back crises — a racist mass shooting and a potentially catastrophic hurricane — could help burnish his image as a can-do, effective governor or further damage his standing with Black Americans who have grown livid over his policies.Already, DeSantis' attempts to show leadership in the immediate aftermath of the Saturday shooting were poorly received by some Black lawmakers, Democrats and residents in Florida. In the hours after a 21-year-old white man killed three Black Floridians near a historically Black college in Jacksonville, several state Democrats blamed DeSantis, who is running for president, for creating an environment, through policies such as loosening gun laws and ending diversity programs, that helped hate fester.DeSantis has condemned the shooting and said “targeting people due to their race has no place in this state of Florida.” But attending a Sunday night vigil in Jacksonville, he was jeered and booed by people who had come out to remember the victims. At one point, a Jacksonville Democratic councilmember stepped in to calm the crowd, urging people to “put parties aside.” Later during the event, a pastor took issue with DeSantis describing the gunman as a “scumbag,” and said he should have used the word “racist” instead.The vigil stood in contrast to press conferences in Tallahassee on Sunday and Monday, when DeSantis appeared visibly tired but spoke authoritatively about preparations overseeing Tropical Storm Idalia, which is forecast to become a major hurricane. He canceled campaign appearances and fundraisers, and told Floridians Sunday they could “rest assured” because “I am here” and would “get the job done.”DeSantis says politics won't interfere with storm response“He needs to be in Florida for as long as it takes,” said Adam Hollingsworth, the former chief of staff to Sen. Rick Scott (R-Fla.), who served as governor before DeSantis. “His presidential ambitions could be a distraction, but first Gov. DeSantis has to dance with the one who brought him. Right now, that's the people of Florida.”Though the shooting and looming storm are taking DeSantis away from campaigning for president following a high-profile debate, they'll also allow voters and donors to see the governor at work leading the hurricane response, letting the public assess how he balances multiple priorities, displays empathy and projects leadership in moments of tragedy. At the same time, the shooting has shined a spotlight on DeSantis' record and vulnerabilities on race, one of the areas for which he has faced the most criticism and controversy as governor.In times of tragedy, opponents are “looking for a misstep,” acknowledged Craig Fugate, who led Florida's emergency division under Gov. Jeb Bush and oversaw FEMA during the Obama administration.“They're looking for something to go wrong — particularly for the opponents; they're looking for something to capitalize on,” Fugate said.DeSantis began his Monday morning hurricane preparedness press conference by first addressing the mass shooting. He pledged $1 million in security funding to Edward Waters University, a historically Black university that the gunman is believed to have initially targeted, as well as $100,000 toward a charity for the families of the victims. He also deployed state law enforcement officials to evaluate the campus' security and make additional recommendations, pledging to continue to assist in the “days and weeks ahead.”But many Democrats in the state panned his response. They pointed to laws he enacted in Florida to carve up representation in a Black-majority district that eventually led a Black Democratic congressman, Rep. Al Lawson, to lose his seat. They also pointed to his policies, approved by the GOP-led Legislature, banning what he calls “critical race theory” in schools, as well as his defense of a public school curriculum on Black history that required middle-school teachers to instruct that enslaved people “developed skills which, in some instances, could be applied for their personal benefit.”Florida Minority House Leader Fentrice Driskell, a Black Democrat of Tampa, said it was “absolutely” the right decision for DeSantis to attend the vigil but added that she didn't want to give him a pass.“The reality is, a number of wrongheaded decisions about the state of Florida, and who we are as a people, I think contributed to this charged political climate that resulted in the violence that we saw,” Driskell said in an interview.The accused gunman, identified as Ryan Palmeter, had a racist manifesto and drew swastikas on his weapons. He also had a history of mental illness, having been involuntarily institutionalized for emergency mental health services as a teenager, police said.During DeSantis' vigil remarks Sunday, Democratic state Rep. Angela Nixon, who represents the district where the shooting took place, could be seen glaring at the governor in videos and photos widely shared on social media.“We feel the same,” the NAACP wrote on X, the social media platform formerly known as Twitter.AXIOS: Biden set to name first 10 drugs subject to Medicare negotiations.The blood-thinners Eliquis and Xarelto are among the 10 prescription medicines the Biden administration will seek lower Medicare prices for as part of a new program allowing the government to negotiate drug prices for America's seniors.Why it matters: The administration's landmark announcement Tuesday detailed the first-ever set of drugs subject to Medicare price negotiations, a longtime Democratic priority included in last year's Inflation Reduction Act over drug companies' fervent objections.Other drugs up for negotiation include:Jardiance, a diabetes drug.Januvia, also for diabetes.Farxiga, another diabetes drug.Entresto, for heart failure.Enbrel, for arthritis and psoriasis.Imbruvica, a blood cancer drug.Stelara, used on psoriasis, Crohn's disease and other illnesses.Fiasp, also used for diabetes.Of note: Insulin is already subject to a $35 monthly co-pay cap for Medicare prescription drug plan enrollees under a different provision of the IRA.State of play: The drugs' manufacturers will have just over a month to decide whether to participate in negotiations — which the industry is battling in court — or sit out the process, at the risk of significant financial penalty.Drugmakers who refuse to negotiate with Medicare face an excise tax of up to 95% of their U.S. sales, or they can withdraw their drugs from Medicare and Medicaid coverage, shutting them out of huge markets.What they're saying: "The cancer moonshot will not succeed if this administration continues to dismantle the innovation rocket we need to get there," Stephen Ubl, CEO of industry trade group PhRMA, said in a statement following the release of the list.Zoom out: The medicines up for negotiation were chosen from a list of the 50 products with the highest spending in Medicare's prescription drug program, Part D.The selected drugs accounted for 20% of Part D prescription costs between June 1, 2022 and May 31, 2023, according to the Health and Human Services Department.Some of the highest-cost Medicare drugs were not eligible for this round of negotiations, either because they still have market exclusivity, they're the only option for a rare disease or another factor.The prices won't take effect before the 2024 elections, but Democrats are expected to tout the negotiations, along with other drug cost reforms in the IRA, as part of their campaign messaging.What's next: The Centers for Medicare and Medicaid Services will submit price offers to the drug companies by Feb. 1, with negotiations continuing until next August.CMS will publish the drugs' final maximum fair prices by Sept. 1, 2024, and prices will go into effect in 2026.What we're watching: Ongoing legal challenges could draw out or halt the negotiation process.Drugmakers and allied groups have already filed eight lawsuits against the Medicare drug negotiation process, and more lawsuits could follow Tuesday's announcement.President Biden and his health officials committed this morning to fighting industry lawsuits."Let me be clear: I am not backing down. There is no reason why Americans should be forced to pay more than any developed nation for life-saving prescriptions just to pad Big Pharma's pockets," Biden said in a statement.Nikki HaleyDAILY BEAST: Is it time for Republicans to take Nikki Haley seriously?According to a new Emerson College Polling survey, “Haley saw the largest increase in support among Republican candidates, jumping 5 points from 2 percent to 7 percent” following last week's debate.“Nikki Haley's support increased from about 2 percent to 9 percent among voters over 50 [years of age],” said Spencer Kimball, executive director of Emerson College Polling, “while Trump's support dropped within this age group from about 56 percent to 49 percent after the debate.”Republican Debaters Agreed on One Thing: They Hate Vivek RamaswamyThis jump is modest, inasmuch as it still leaves Haley in the single digits. But it's also no outlier. According to a poll conducted by The Washington Post, FiveThirtyEight, and Ipsos released last Thursday, voters were persuaded to at least give her a second look. “Pre-debate, 29 percent of GOP primary voters who watched the debate said they were considering voting for her,” according to the survey, “and that increased to 46 percent after the debate.”So how did she do it? Haley caught our attention by being first to hit Trump (from the right), when she criticized him for “adding eight trillion to our debt.” This surprised everyone, demonstrated courage, and put to rest the notion that she is merely running to be Trump's vice president.Haley also staked out a strong position on abortion. While stressing her pro-life beliefs, she made the pragmatic case that a federal abortion ban would require 60 votes. Instead, Haley urged Republicans to focus on consensus issues, like banning late-term abortions, making sure contraception is widely available, and supporting adoption as an alternative.Trump's former veep, Mike Pence, who supports a 15-week federal ban on abortion, took umbrage with this. “Nikki, you're my friend, but consensus is the opposite of leadership,” Pence scolded. (As the Never Trump conservative writer Jonah Goldberg has pointed out on his podcast, building consensus is often a key attribute of leadership.)The Republican Debate Was a Futile Pudding Wrestling MatchThis exchange, like others during that same debate, made it clear that in a general election Nikki Haley would likely be Joe Biden's most challenging opponent.Having served as governor of South Carolina and ambassador to the United Nations, she has the experience needed for the office. She also has sharp elbows. (“You have no foreign policy experience and it shows,” she told Vivek Ramaswamy.)At 51, Haley would present a stark contrast in terms of generational change, assuming that Joe Biden was still the Democratic nominee. And (unlike others) she is not staking out an abortion position that might render her effectively unelectable, should she become the Republican nominee.Haley (who frequently cites Margaret Thatcher's line, “If you want something said, ask a man. If you want something done, ask a woman”) was the only woman on that stage. Her identity, temperament, and policy positions could help chip away at the gender gap that has only grown in recent years.The obvious caveat here is that all of these things would make Haley a great candidate to beat Joe Biden if she somehow wins the Republican nomination. But that's an awfully big “if.”Kareem Abdul-Jabbar: GOP Debate Showed How Not to Pick a PresidentHaley's answer to this is to make the electability argument: “We have to face the fact that Trump is the most disliked politician in America,” she—and she, alone—averred during last week's debate.But will that dog hunt?Right now, the electability argument isn't persuading Republicans to jump off the Trump bandwagon, even though that argument is likely the only one that could ever work. At some point (perhaps after Donald Trump goes on trial and it's too late), Republicans might be convinced that, as entertaining as Trump is, he simply can't win.Based on all of this, you might expect me to suggest that it's time to clear the field—to rally every freedom conservative, Reagan Republican, and Never Trump conservative to coalesce around Haley as the GOP's last, best hope.Some of my colleagues are already there. The New York Times columnist David Brooks, for example, declared last week that “Wednesday's debate persuaded me that the best Trump alternative is not [Tim] Scott, it's Nikki Haley.”But here's my problem. Haley has been all over the map for years now. One day she's courageous and impressive, and the next day she's a pathetic Trump toady.Haley is a political chameleon, which makes me reluctant to ever trust her again.Trump and Ramaswamy Show Us How the Worst Get to the TopOn the other hand, anyone looking for purity (as it pertains to Trump) can also dismiss Pence and Chris Christie—both of whom supported Trump until Jan. 6—and a vast swath of today's leading Never Trumpers. As the Good Book says, “Who then can be saved?”Nikki Haley's got a long way to go before she clears the not-Trump lane of candidates, much less taking on the final boss himself. And though nothing has yet made a dent in Trump's domination of the GOP voter base, he's never run as a candidate on trial before. But the whole 91-felony indictment thing might just do the trick.If Haley can prove herself by stringing together two or three of these kinds of courageous performances—in which she not only characterizes Trump as the guy who already lost to Biden, but also that she's as real a conservative as any of the other contenders—there is a path to success.It's hardly guaranteed, and as I've noted, courage comes and goes with Haley. But in the “Matt Lewis primary,” you can count me among the 46 percent who are now considering voting for her.Read more at The Daily Beast.SEMAFOR: Nikki Haley's abortion message could catch on in the GOPMorgan Chalfant and Kadia GobaRepublicans worried about Democrats leveraging abortion (again) to make gains in 2024 want GOP candidates to take a page out of Nikki Haley's debate prep playbook.Haley dismissed the idea that a 15-week national abortion ban could pass through Congress. Instead, she argued the focus should be on finding “consensus” around banning “late-term abortions,” sustaining access to contraception, allowing doctors who don't support abortion refuse to perform them, and preventing women who get abortions from being penalized.Defeated Michigan gubernatorial candidate Tudor Dixon bluntly said on Fox News that Republicans would lose the messaging war in 2024 unless they followed Haley's “perfect response” in the debate.“No one really understood how important abortion would be in 2022 because no one had run in a post-Roe world, so we suddenly got attacked, viciously attacked, by the Democrats, and it is a winning message for them,” she said. Gov. Gretchen Whitmer highlighted Dixon's opposition to rape exceptions in abortion bans in their contest, which took place alongide a ballot initiative guaranteeing abortion rights that passed by a wide margin.“The only candidate on the stage that talked about how we should protect women and not demonize them was Nikki Haley,” Rep. Nancy Mace, R-S.C. said Sunday on CBS of the first GOP presidential debate. “And that is a message that we have to carry through. We have to be pro-woman and pro-life. You cannot go after women and attack them because they make a choice that you don't like or don't agree with.”And Rep. George Santos, R-N.Y., who represents a district President Biden won in 2020, told Semafor at a watch party last week: “She had probably the best-packaged message on abortion that I've heard, I want to say, in my entire adult life.”Haley might have won herself some fans, but her position wasn't a favorite within the anti-abortion movement, which has rallied around a 15-week federal ban as a minimum ask for candidates.

Florida Gov and GOP 2024 also-ran Ron DeSantis looks to lead in wake of violence and major hurricane | Former SC Gov and UN Ambassador under President Trump, Nikki Haley is having a moment, kind of | President Biden names first 10 drugs subject to negotations with Medicare | 60th anniversary of the March on WashingtonSong playsIntro by hostWelcome to Heartland Pod Wednesday!Support this show and all the work in the Heartland POD universe by going to heartlandpod.com and clicking the link for Patreon, or go to Patreon.com/HeartlandPod to sign up. Membership starts at $1/month, with even more extra shows and special access at the higher levels. No matter the level you choose, your membership helps us create these independent shows as we work together to change the conversation.Alright! Let's get into it: Hurricane in Florida / Shooting in FloridaPOLITICO: DeSantis knows how to handle a hurricane. The racist shooting poses a bigger dilemma.A racially-motivated Jacksonville tragedy, couple with a looming storm, pose big tests for the governor.Florida Gov. Ron DeSantis, center and his wife Casey, right, bow their heads during a prayer.Florida Gov. Ron DeSantis (center) and his wife Casey bow their heads during a prayer at a vigil for the victims of Saturday's mass shooting on Sunday, Aug. 27, 2023, in Jacksonville. | John Raoux/AP PhotoBy KIMBERLY LEONARD08/28/2023 04:14 PM EDTUpdated: 08/28/2023 05:12 PM EDTMIAMI — Florida Gov. Ron DeSantis' handling of back-to-back crises — a racist mass shooting and a potentially catastrophic hurricane — could help burnish his image as a can-do, effective governor or further damage his standing with Black Americans who have grown livid over his policies.Already, DeSantis' attempts to show leadership in the immediate aftermath of the Saturday shooting were poorly received by some Black lawmakers, Democrats and residents in Florida. In the hours after a 21-year-old white man killed three Black Floridians near a historically Black college in Jacksonville, several state Democrats blamed DeSantis, who is running for president, for creating an environment, through policies such as loosening gun laws and ending diversity programs, that helped hate fester.DeSantis has condemned the shooting and said “targeting people due to their race has no place in this state of Florida.” But attending a Sunday night vigil in Jacksonville, he was jeered and booed by people who had come out to remember the victims. At one point, a Jacksonville Democratic councilmember stepped in to calm the crowd, urging people to “put parties aside.” Later during the event, a pastor took issue with DeSantis describing the gunman as a “scumbag,” and said he should have used the word “racist” instead.The vigil stood in contrast to press conferences in Tallahassee on Sunday and Monday, when DeSantis appeared visibly tired but spoke authoritatively about preparations overseeing Tropical Storm Idalia, which is forecast to become a major hurricane. He canceled campaign appearances and fundraisers, and told Floridians Sunday they could “rest assured” because “I am here” and would “get the job done.”DeSantis says politics won't interfere with storm response“He needs to be in Florida for as long as it takes,” said Adam Hollingsworth, the former chief of staff to Sen. Rick Scott (R-Fla.), who served as governor before DeSantis. “His presidential ambitions could be a distraction, but first Gov. DeSantis has to dance with the one who brought him. Right now, that's the people of Florida.”Though the shooting and looming storm are taking DeSantis away from campaigning for president following a high-profile debate, they'll also allow voters and donors to see the governor at work leading the hurricane response, letting the public assess how he balances multiple priorities, displays empathy and projects leadership in moments of tragedy. At the same time, the shooting has shined a spotlight on DeSantis' record and vulnerabilities on race, one of the areas for which he has faced the most criticism and controversy as governor.In times of tragedy, opponents are “looking for a misstep,” acknowledged Craig Fugate, who led Florida's emergency division under Gov. Jeb Bush and oversaw FEMA during the Obama administration.“They're looking for something to go wrong — particularly for the opponents; they're looking for something to capitalize on,” Fugate said.DeSantis began his Monday morning hurricane preparedness press conference by first addressing the mass shooting. He pledged $1 million in security funding to Edward Waters University, a historically Black university that the gunman is believed to have initially targeted, as well as $100,000 toward a charity for the families of the victims. He also deployed state law enforcement officials to evaluate the campus' security and make additional recommendations, pledging to continue to assist in the “days and weeks ahead.”But many Democrats in the state panned his response. They pointed to laws he enacted in Florida to carve up representation in a Black-majority district that eventually led a Black Democratic congressman, Rep. Al Lawson, to lose his seat. They also pointed to his policies, approved by the GOP-led Legislature, banning what he calls “critical race theory” in schools, as well as his defense of a public school curriculum on Black history that required middle-school teachers to instruct that enslaved people “developed skills which, in some instances, could be applied for their personal benefit.”Florida Minority House Leader Fentrice Driskell, a Black Democrat of Tampa, said it was “absolutely” the right decision for DeSantis to attend the vigil but added that she didn't want to give him a pass.“The reality is, a number of wrongheaded decisions about the state of Florida, and who we are as a people, I think contributed to this charged political climate that resulted in the violence that we saw,” Driskell said in an interview.The accused gunman, identified as Ryan Palmeter, had a racist manifesto and drew swastikas on his weapons. He also had a history of mental illness, having been involuntarily institutionalized for emergency mental health services as a teenager, police said.During DeSantis' vigil remarks Sunday, Democratic state Rep. Angela Nixon, who represents the district where the shooting took place, could be seen glaring at the governor in videos and photos widely shared on social media.“We feel the same,” the NAACP wrote on X, the social media platform formerly known as Twitter.AXIOS: Biden set to name first 10 drugs subject to Medicare negotiations.The blood-thinners Eliquis and Xarelto are among the 10 prescription medicines the Biden administration will seek lower Medicare prices for as part of a new program allowing the government to negotiate drug prices for America's seniors.Why it matters: The administration's landmark announcement Tuesday detailed the first-ever set of drugs subject to Medicare price negotiations, a longtime Democratic priority included in last year's Inflation Reduction Act over drug companies' fervent objections.Other drugs up for negotiation include:Jardiance, a diabetes drug.Januvia, also for diabetes.Farxiga, another diabetes drug.Entresto, for heart failure.Enbrel, for arthritis and psoriasis.Imbruvica, a blood cancer drug.Stelara, used on psoriasis, Crohn's disease and other illnesses.Fiasp, also used for diabetes.Of note: Insulin is already subject to a $35 monthly co-pay cap for Medicare prescription drug plan enrollees under a different provision of the IRA.State of play: The drugs' manufacturers will have just over a month to decide whether to participate in negotiations — which the industry is battling in court — or sit out the process, at the risk of significant financial penalty.Drugmakers who refuse to negotiate with Medicare face an excise tax of up to 95% of their U.S. sales, or they can withdraw their drugs from Medicare and Medicaid coverage, shutting them out of huge markets.What they're saying: "The cancer moonshot will not succeed if this administration continues to dismantle the innovation rocket we need to get there," Stephen Ubl, CEO of industry trade group PhRMA, said in a statement following the release of the list.Zoom out: The medicines up for negotiation were chosen from a list of the 50 products with the highest spending in Medicare's prescription drug program, Part D.The selected drugs accounted for 20% of Part D prescription costs between June 1, 2022 and May 31, 2023, according to the Health and Human Services Department.Some of the highest-cost Medicare drugs were not eligible for this round of negotiations, either because they still have market exclusivity, they're the only option for a rare disease or another factor.The prices won't take effect before the 2024 elections, but Democrats are expected to tout the negotiations, along with other drug cost reforms in the IRA, as part of their campaign messaging.What's next: The Centers for Medicare and Medicaid Services will submit price offers to the drug companies by Feb. 1, with negotiations continuing until next August.CMS will publish the drugs' final maximum fair prices by Sept. 1, 2024, and prices will go into effect in 2026.What we're watching: Ongoing legal challenges could draw out or halt the negotiation process.Drugmakers and allied groups have already filed eight lawsuits against the Medicare drug negotiation process, and more lawsuits could follow Tuesday's announcement.President Biden and his health officials committed this morning to fighting industry lawsuits."Let me be clear: I am not backing down. There is no reason why Americans should be forced to pay more than any developed nation for life-saving prescriptions just to pad Big Pharma's pockets," Biden said in a statement.Nikki HaleyDAILY BEAST: Is it time for Republicans to take Nikki Haley seriously?According to a new Emerson College Polling survey, “Haley saw the largest increase in support among Republican candidates, jumping 5 points from 2 percent to 7 percent” following last week's debate.“Nikki Haley's support increased from about 2 percent to 9 percent among voters over 50 [years of age],” said Spencer Kimball, executive director of Emerson College Polling, “while Trump's support dropped within this age group from about 56 percent to 49 percent after the debate.”Republican Debaters Agreed on One Thing: They Hate Vivek RamaswamyThis jump is modest, inasmuch as it still leaves Haley in the single digits. But it's also no outlier. According to a poll conducted by The Washington Post, FiveThirtyEight, and Ipsos released last Thursday, voters were persuaded to at least give her a second look. “Pre-debate, 29 percent of GOP primary voters who watched the debate said they were considering voting for her,” according to the survey, “and that increased to 46 percent after the debate.”So how did she do it? Haley caught our attention by being first to hit Trump (from the right), when she criticized him for “adding eight trillion to our debt.” This surprised everyone, demonstrated courage, and put to rest the notion that she is merely running to be Trump's vice president.Haley also staked out a strong position on abortion. While stressing her pro-life beliefs, she made the pragmatic case that a federal abortion ban would require 60 votes. Instead, Haley urged Republicans to focus on consensus issues, like banning late-term abortions, making sure contraception is widely available, and supporting adoption as an alternative.Trump's former veep, Mike Pence, who supports a 15-week federal ban on abortion, took umbrage with this. “Nikki, you're my friend, but consensus is the opposite of leadership,” Pence scolded. (As the Never Trump conservative writer Jonah Goldberg has pointed out on his podcast, building consensus is often a key attribute of leadership.)The Republican Debate Was a Futile Pudding Wrestling MatchThis exchange, like others during that same debate, made it clear that in a general election Nikki Haley would likely be Joe Biden's most challenging opponent.Having served as governor of South Carolina and ambassador to the United Nations, she has the experience needed for the office. She also has sharp elbows. (“You have no foreign policy experience and it shows,” she told Vivek Ramaswamy.)At 51, Haley would present a stark contrast in terms of generational change, assuming that Joe Biden was still the Democratic nominee. And (unlike others) she is not staking out an abortion position that might render her effectively unelectable, should she become the Republican nominee.Haley (who frequently cites Margaret Thatcher's line, “If you want something said, ask a man. If you want something done, ask a woman”) was the only woman on that stage. Her identity, temperament, and policy positions could help chip away at the gender gap that has only grown in recent years.The obvious caveat here is that all of these things would make Haley a great candidate to beat Joe Biden if she somehow wins the Republican nomination. But that's an awfully big “if.”Kareem Abdul-Jabbar: GOP Debate Showed How Not to Pick a PresidentHaley's answer to this is to make the electability argument: “We have to face the fact that Trump is the most disliked politician in America,” she—and she, alone—averred during last week's debate.But will that dog hunt?Right now, the electability argument isn't persuading Republicans to jump off the Trump bandwagon, even though that argument is likely the only one that could ever work. At some point (perhaps after Donald Trump goes on trial and it's too late), Republicans might be convinced that, as entertaining as Trump is, he simply can't win.Based on all of this, you might expect me to suggest that it's time to clear the field—to rally every freedom conservative, Reagan Republican, and Never Trump conservative to coalesce around Haley as the GOP's last, best hope.Some of my colleagues are already there. The New York Times columnist David Brooks, for example, declared last week that “Wednesday's debate persuaded me that the best Trump alternative is not [Tim] Scott, it's Nikki Haley.”But here's my problem. Haley has been all over the map for years now. One day she's courageous and impressive, and the next day she's a pathetic Trump toady.Haley is a political chameleon, which makes me reluctant to ever trust her again.Trump and Ramaswamy Show Us How the Worst Get to the TopOn the other hand, anyone looking for purity (as it pertains to Trump) can also dismiss Pence and Chris Christie—both of whom supported Trump until Jan. 6—and a vast swath of today's leading Never Trumpers. As the Good Book says, “Who then can be saved?”Nikki Haley's got a long way to go before she clears the not-Trump lane of candidates, much less taking on the final boss himself. And though nothing has yet made a dent in Trump's domination of the GOP voter base, he's never run as a candidate on trial before. But the whole 91-felony indictment thing might just do the trick.If Haley can prove herself by stringing together two or three of these kinds of courageous performances—in which she not only characterizes Trump as the guy who already lost to Biden, but also that she's as real a conservative as any of the other contenders—there is a path to success.It's hardly guaranteed, and as I've noted, courage comes and goes with Haley. But in the “Matt Lewis primary,” you can count me among the 46 percent who are now considering voting for her.Read more at The Daily Beast.SEMAFOR: Nikki Haley's abortion message could catch on in the GOPMorgan Chalfant and Kadia GobaRepublicans worried about Democrats leveraging abortion (again) to make gains in 2024 want GOP candidates to take a page out of Nikki Haley's debate prep playbook.Haley dismissed the idea that a 15-week national abortion ban could pass through Congress. Instead, she argued the focus should be on finding “consensus” around banning “late-term abortions,” sustaining access to contraception, allowing doctors who don't support abortion refuse to perform them, and preventing women who get abortions from being penalized.Defeated Michigan gubernatorial candidate Tudor Dixon bluntly said on Fox News that Republicans would lose the messaging war in 2024 unless they followed Haley's “perfect response” in the debate.“No one really understood how important abortion would be in 2022 because no one had run in a post-Roe world, so we suddenly got attacked, viciously attacked, by the Democrats, and it is a winning message for them,” she said. Gov. Gretchen Whitmer highlighted Dixon's opposition to rape exceptions in abortion bans in their contest, which took place alongide a ballot initiative guaranteeing abortion rights that passed by a wide margin.“The only candidate on the stage that talked about how we should protect women and not demonize them was Nikki Haley,” Rep. Nancy Mace, R-S.C. said Sunday on CBS of the first GOP presidential debate. “And that is a message that we have to carry through. We have to be pro-woman and pro-life. You cannot go after women and attack them because they make a choice that you don't like or don't agree with.”And Rep. George Santos, R-N.Y., who represents a district President Biden won in 2020, told Semafor at a watch party last week: “She had probably the best-packaged message on abortion that I've heard, I want to say, in my entire adult life.”Haley might have won herself some fans, but her position wasn't a favorite within the anti-abortion movement, which has rallied around a 15-week federal ban as a minimum ask for candidates.

Our transcription service is still very BETA. Get full access to INDIGNITY at indignity.substack.com/subscribe

This week AFK joins Sam and Jeff for a little chit chat.  We touch on a range of topics!  Irish Goodbyes, Scary Movies, Donut Walls, and so much more!  We watched content galore, Acting Camp, Talk to Me, The Lincoln Lawyer, Heart Stoppers, and Painkiller.Jeff met a new boy and did not play cards. SHOCKING.

Garry discusses why you should not brush your teeth in the shower. Plus, Garry revisits the Jardiance commercial one more time!

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: FDA approval for a pancreatic islet cell therapy to treat type 1, stem cell research moves ahead, big news from the ADA Scientific Sessions about what's next for medications like Mounjaro and a pill form of semaglutide. Dexcom announces a sensor for people with type 2 who don't use insulin, Libre moves ahead with Ketone monitoring and more.   Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by the T1D Exchange a nonprofit organization dedicated to improving outcomes for the entire T1D population. XX Big week of news following the 2023 ADA Scientific Sessions conference. What follows is just the tip of the information iceberg, so please follow the links in the show notes to much more. -- XX Top story though isn't from ADA – but a new FDA approval.. for a pancreatic islet cell therapy to treat type 1. It's called donislecel, developed from cadaver donors and giving as a single infusion straight into the liver. Immunosuppression is required to maintain cell viability, just as it is required to support a transplanted kidney or other organ. Approval was based on what seems to be a very small study – 30 people with type 1 who had hypoglycemic unawareness and who received between one and three infusions of donislecel. After one year, 11 people did not need to dose insulin.. 10 stayed that way for more than five years. But five people in the study were not able to stop dosing insulin at all. This method is different from what Vertex and Sernova are trying to do with stem cell therapy. https://www.medscape.com/viewarticle/993854 XX Vertex moves forward on their clinical trial of islet stem cell therapy. All six patients treated with VX-880 had undetectable fasting C-peptide (endogenous insulin secretion) at baseline, a history of recurrent SHEs in the year prior to treatment and required an average of 34.0 units of insulin per day. Following treatment, all six patients demonstrated endogenous insulin secretion, improved glycemic control as measured by HbA1c, improved time-in-range on continuous glucose monitoring, and reduction or elimination of exogenous insulin use. Two patient are completely insulin independent after one year – with an A1C of 5.3 compard to 8.6 at baseline.. the other 6.0 with a 7.6 at baseline – again the ”after” number is without taking insulin. As a result of these safety and efficacy data in Parts A and B, the independent data review committee has recommended moving to Part C of the trial, which allows for concurrent dosing of patients at the full target dose of VX-880. https://www.businesswire.com/news/home/20230623446641/en/Vertex-Presents-Positive-VX-880-Results-From-Ongoing-Phase-12-Study-in-Type-1-Diabetes-at-the-American-Diabetes-Association-83rd-Scientific-Sessions XX Sernova also reports good results with their cell pouch system. Five of the six patients who have completed implantation continue to experience insulin independence for periods ranging from six months to more than three years. The sixth patient only recently completed the protocol-defined islet transplants.. so no results yet. There is a second group testing a larger cell pouch. https://www.drugdeliverybusiness.com/sernova-interim-data-cell-pouch-system/ XX Big news from ADA about all of the type 2 and obesity drugs you've likely heard about.. here are some headlines: SURMOUNT-2 clinical trial evaluating tirzepatide – brand name Mounjaro - for weight loss in adults with obesity or overweight and type 2 diabetes. Average weight loss was 15.7% at the highest dose, with many other health benefits such as lower A1C levels; reduction in waist circumference, and body mass index; and improvements in cardiometabolic disease risk factors such as lipid levels, cholesterol, and blood pressure. That 15 percent weight loss was about 34 pounds and the a1c reduction for half of those in the study went down to 5.7 which is considered nondiabetic. Mounjaro is currently approved for type 2 and the FDA could approve Mounjaro regardless of diabetes status later this year. https://diatribe.org/new-lilly-trial-results-show-big-weight-loss-results-positioning-mounjaro-obesity-drug-approval XX A study called PIONEER looks at oral semaglutides – some calling it the Ozempic pill. When compared to other anti-diabetic medications such as Jardiance, Januvia and Victoza, people taking the oral semaglutide say 1% or or more reduction of HbA1c compared to those treated with other anti-diabetic medicines. They also were more like to achieve a 5% or more reduction of body weight. Note: this was not a study comparing a semaglutide pill with the same type of injection. https://www.news-medical.net/news/20230607/Oral-semaglutide-outperforms-other-medications-in-type-2-diabetes-treatment-significantly-reducing-HbA1c-and-body-weight.aspx XX And look for two additional new drugs to treat obesity in the next few years.. orforglipron, is easier to use and to produce, and it will probably be cheaper than existing treatments. The second, retatrutide, has an unprecedented level of efficacy, and could raise the bar for pharmacological obesity treatment. Orforglipron and retatrutide both mimic hormones produced by the lining of the gut in response to certain nutrients. These hormones help to slow the passage of food through the digestive tract and lower appetite by acting on receptors in the brain — both effects that reduce people's desire to eat and help them to lose weight. Orfoglipron is a non-peptide molecule that researchers say is easy to produce and is a pill.. a lower price is anticipated for this one. Retratritude looks like it could help people lose even more weight than Mounjaro. https://www.nature.com/articles/d41586-023-02092-9 XX Dexcom announces a new product in the US – coming in 2024 – designed for people with type 2 who don't use insulin. This will be built on the G7 hardware, but with different software and a 15 day sensor. CEO Kevin Sayer also announced that the G7 will be able to share data direct to the apple watch https://www.businesswire.com/news/home/20230623025076/en/Global-Continuous-Glucose-Monitoring-Pioneer-Dexcom-Reveals-New-Plans-to-Bring-Sensing-Technology-to-Millions-More XX Abbott will partner with Weight Watchers - people who have been prescribed one of Abbott's FreeStyle Libre 14-Day or FreeStyle Libre 2 sensors and who are using the WeightWatchers diet plan to see their CGM data directly in the WeightWatchers app. This is also a study where Abbott will launch two pilot programs directed at using CGM data to help people with Type 2 diabetes adjust and manage their dietary habits, regardless of whether they're on insulin therapy. XX A little bit more news about Abbott's dual glucose and ketone sensor under development. Announced a last year's ADA, the company says it's moving forward through R&D Separately from the Type 2 CGM push, Taub also offered an update on the dual glucose ketone sensor that's currently under development at Abbott and that the company first announced at last year's ADA conference. The sensor will be aimed at catching rising ketone levels as early as possible to help avoid cases of diabetic ketoacidosis. An Abbot executive says – quote - “There's so much that we stand to learn about ketones because there hasn't been a continuous sensor for them before, so there's really very little we know about the evolution of ketones “ https://www.fiercebiotech.com/medtech/ada-abbott-pushes-widespread-cgm-use-type-2-diabetes-weightwatchers-ada-collabs XX Commercial XX Beta Bionics has received FDA 510(k) clearance for the compatibility of the Fiasp Pumpcart prefilled insulin cartridge with the iLet automated insulin-delivery system. The iLet is a bionic pancreas that fully automates 100% of all user insulin doses, providing users with the choice of three insulins, Novolog; Humalog; and Fiasp Pumpcart. The device eases diabetes management in everyday life and almost eliminates the expertise that has been required in the past to set up and manage a traditional insulin pump. In May 2023, Beta Bionics was awarded FDA approval for the iLet device. The iLet manages glucose levels with just a meal announcement and is paired with a Dexcom G6 Continuous Glucose Monitoring System for glucose readings. All that is required for set-up is the user's weight. While there is a need for carbohydrate awareness, no carb counting is necessary. Bolusing, correction factors, insulin-to-carb ratios, and pre-set basal rates are also unnecessary. Beta Bionics president and CEO Sean Saint said: “Beta Bionics has been working tirelessly to create an insulin delivery system that offers less burden and more convenience for the type 1 community. Since launching last month, the iLet bionic pancreas is now available and clinics and users are being trained on its simple design and easy management features. “When Fiasp Pumpcart prefilled cartridges are available, users will save time not having to manually fill cartridges and will have more choice for their diabetes management.” https://www.medicaldevice-network.com/news/beta-bionics-gains-fda-clearance-for-prefilled-insulin-cartridge/ XX Oura – the ring that tracks your sleep – will start sending info to three CGM info companies.. January, Supersapiens and Veri. All three of these companies provide software based off of the Libre CGM. These companies will now be receiving sleep scores and other biometric data from Oura so they can see how these measurements affect users' glucose levels and overall health. https://www.forbes.com/sites/andrewwilliams/2023/06/27/oura-smart-ring-can-be-used-to-help-monitor-blood-sugar/?sh=2520116c2b10 XX Just a fun fact here – there is a Facebook group called type 1 diabetics for 50 plus years. And it looks like this week they passed over 1500 members. XX On the podcast next week.. I sat down with Dexcom's new Chief Commercial officer to talk about their announcements from this week about the type 2 market and other features important to people with type 1. Our last epoisde is all about Kickass Healthy LADA That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Garry provides commentary around the breaking news that Ryan Seacrest will be the new Wheel of Fortune host. Plus, more talk about the great Jardiance dance number.

Get our free download! Implementing AMA Style – 8 Things to Get Right In this episode, we discuss the latest FDA approvals from June 19 –  June 23, 2023.  Here are the key highlights: ·       The FDA has given approval to Pfizer's Talzenna and Xtandi for treating metastatic castration-resistant prostate cancer in adults with certain genetic mutations. The approval came following successful Phase 3 TALAPRO-2 trial results. ·       Sarepta Therapeutics' Elevidys, a gene therapy for Duchenne muscular dystrophy, has received accelerated approval from the FDA. Elevidys, the first gene therapy of its kind, is approved for ambulatory pediatric patients aged 4-5 years with confirmed mutation in the DMD gene. ·       Jardiance and Synjardy, initially approved for adults in 2014 and 2015 respectively, have now been approved by the FDA for use in children aged 10 and older with type 2 diabetes. This approval came on the back of the DINAMO phase 3 trial results. ·       Pfizer's Litfulo, a once-daily oral treatment for severe alopecia areata for individuals aged 12 and older, has received FDA approval. This is the first treatment approved for adolescents with this condition.  ·       Amgen's Blincyto has received FDA approval for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) in first or second complete remission with minimal residual disease. This moves the drug from an accelerated approval to a full approval status. ·       Argenx's Vyvgart Hytrulo, a subcutaneous version of the original drug Vyvgart, has been approved by the FDA. It is indicated for generalized myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine receptor antibodies. ·       Bayer's Ultravist (iopromide) injection, the first contrast agent for contrast-enhanced mammography, has been approved by the FDA. This new imaging tool enhances visibility of suspected or known breast lesions. ·       The FDA has refused to grant accelerated approval to Intercept Pharmaceuticals' drug obeticholic acid (OCA) for treating non-alcoholic steatohepatitis (NASH). This is the second time the FDA has declined to approve the drug for NASH due to potential risks. ·       Please check back every Monday morning for last week's approvals so that you can stay up to date.  See all the episodes here. ·       This podcast is brought to you by Nascent Medical. If you're a project manager at a CME or medical communications agency and need on-call medical writing assistance please visit Nascent Medical. We are a team of MD- and PhD-level medical writers and can create slide decks, white papers, ad board summaries, manuscripts, needs assessments, and much more. We also do medical editing using AMA style and factchecking. Visit nascentmc.com  ·       Intro and outro music ·       Garden Of Love by Pk jazz Collective

Tune in every Friday for more WOW Report. 10) S.O.S. TCM: Bloodbath at Turner Classic Movies @02:12 9) Hot Comedy Special: Matthew Steven Rife @07:57 8) Find-A-Queen with SeetheQueens.com @11:39 7) HBO's The Idol @21:53 6) Songs of the Summer @27:44 5) The Future Perfect Project @31:10 4) Watch Queen of the Universe While You Can! @37:03 3) Titanic Redux @41:52 2) Trey's Ten Year WOW-versary @47:40 1) Our Favorite LGBTQIA Movies @53:01

Shownotes: 0:01:04 Metformin and Diabetes 0:02:48 Metformin Monotherapy 0:06:46 Are There Any Geroprotective Benefits From Taking Metformin? 0:10:50 Benefits of Rapamycin and 0:12:14 Acarbose and Sugar Metabolism 0:16:28 SGL2 inhibitor Jardiance 0:20:37 Glucose Monitoring and Metformin

People have increasingly been turning to peptide therapies to help manage health conditions alongside conventional medical care. And over the past year, we've talked about many of these peptides and how people have used them to support the body's own healing mechanisms, treat pain, improve function, find relief from certain symptoms, and improve quality of life. But we haven't talked in depth about the importance of hydration. Drinking enough water each day is important for many reasons. Water helps keep our joints lubricated, delivers nutrients to our cells, keeps our organs working properly, and prevents infections. It also helps regulate our temperature, prevents constipation, and removes harmful waste through pee, sweat, and poop. Hydration also helps boost energy levels and helps with mood and memory.  How much water should I drink? The general rule is to take your total body weight in pounds and divide the number in half. This is about how many ounces of water you should drink each day. For example, a person who weighs 250 lbs should drink about 125 ounces or 3.6 liters of water daily. This is about six 20-ounce bottles of water daily. Most people's everyday eating and drinking habits will help them meet their body's daily water needs. Simply put, if you drink fluids when you're thirsty and eat food when you're hungry, you're probably getting enough water each day. All beverages, including tea, coffee, milk, soda, and juice, have water. But it's best to choose water or low-calorie or calorie-free drinks for hydration. High-calorie beverages like regular soda and juice can lead to weight gain and inflammation, increasing your risk for type 2 diabetes and heart disease. Foods like cucumber, iceberg lettuce, watermelon, cantaloupe, strawberries, and zucchini have more than 90% water.  How do I avoid dehydration? It's important to remember that some people may need to drink more water than others. For example, people in hotter, dry climates lose more water through sweat and may need to drink more water to replace the fluids they lose.   Also, if you're physically active (e.g., physically demanding job, exercising), you should increase your water intake to stay hydrated. This is especially important if you're working out or moving around outside in hot weather. And some people with certain infections or medical conditions (e.g., IBS, Crohn's disease, ulcerative colitis, pregnancy) that cause diarrhea or vomiting may also need to drink more water.  It's also recommended to increase your water intake during menopause and breastfeeding to stay hydrated. Breastfeeding can cause fluid loss through breast milk. And during menopause, the body may not be as good at self-regulating its hydration due to hormone changes. Medications like Jardiance, Invokana, and Farxiga are used for type 2 diabetes, and diuretics used to treat conditions like high blood pressure and heart failure make you pee more. Because of this, people taking these medications need to drink more water to prevent dehydration.  And people taking chemotherapy may also need to drink more water as it can cause a lot of vomiting and diarrhea, which could lead to dehydration. How can I tell if I'm getting enough water? An excellent way to tell if you're hydrated is to look at your pee. If the color of your pee is clear to pale yellow, you're getting enough water. On the other hand, if the color of your pee is dark yellow or brown, it may be a sign that you need to drink more water.   Other signs that you may need to drink more water would be that you're peeing less or your pee smells different or bad. You could also have a dry mouth or lips or dry skin. Some people also have headaches, dizziness, and muscle cramping.  Thanks again for listening to The Peptide Podcast, we love having you as part of our community. If you love this podcast, please share it with your friends and family on social media, and have a happy, healthy week! Pro Tips We're huge advocates of using daily collagen peptide supplements in your routine to help with skin, nail, bone, and joint health. But what do you know about peptides for health and wellness? Giving yourself a peptide injection can be scary or confusing. But we've got you covered. Check out 6 tips to make peptide injections easier. And, make sure you have the supplies you'll need. This may include syringes, needles, alcohol pads, and a sharps container.

Episode 138: SGLT-2 Inhibitors in heart failureFuture doctor Enuka explains the use of sodium-glucose-linked cotransporter-2 inhibitors (SGLT-2 inhibitors) in heart failure. Dr. Arreaza adds his experience with these medications and emphasizes their role as an effective treatment for type 2 diabetes.  Written by  Princess Enuka, MSIV, Ross University School of Medicine. Editing by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Intro:Heart failure is a major medical condition that affects millions of people worldwide. It is one of the leading causes of hospitalization and death in developed countries. Recently, SGLT2 inhibitors have emerged as a promising treatment option for heart failure. Today, we will discuss their benefits, their effectiveness, and their adverse effects.SGLT2 inhibitors, also known as sodium-glucose-linked cotransporter-2 inhibitors, are a relatively novel class of drugs that have shown promise in heart failure treatment. This transporter reabsorbs glucose from the glomerular filtrate back into the bloodstream. Under normal circumstances, SGLT-2 reabsorbs 100% of the filtered glucose unless it is saturated (as in hyperglycemia) or blocked by medications. SGLT2 inhibitors increase the amount of glucose excreted in the urine, which leads to blood glucose reduction. Examples include empagliflozin, dapagliflozin, and canagliflozin.SGLT-2 inhibitors have become a first-line therapy for diabetes mellitus. I heard before that it was used in Europe for T1DM, but it seems like they are no longer used, according to my most recent review of articles. SGLT2 inhibitors are not approved by the FDA for use in type 1 diabetes due to the risk of DKA. Princess, besides the benefits in diabetes, what else did you find in your review?Benefits/Efficacy:SGLT2 inhibitors have additional benefits beyond their glucose-lowering effects. One of the benefits of SGLT2 inhibitors is their ability to increase myocardial energy production, alleviate systemic microvascular dysfunction, and improve systemic endothelial function. Natriuresis and glucosuria mediated by SGLT2 inhibitors have been shown to lower cardiac pre-load and reduce pulmonary congestion and systemic edema, which is beneficial for heart failure management.Studies have shown that these drugs can also improve cardiovascular outcomes in patients with heart failure with a reduced ejection fraction. Some studies:The EMPEROR-Reduced trial demonstrated that empagliflozin, brand name Jardiance®, reduced the risk of cardiovascular death and hospitalization for heart failure in patients with reduced ejection fraction by 25% compared to placebo. Several clinical trials have also shown that this result is significant whether patients have type 2 diabetes or not. Also, in a multicenter, double-blind, randomized, placebo-controlled trial in patients with heart failure, treatment with dapagliflozin, brand name Farxiga®, improved heart failure-related symptoms and physical limitations after only 12 weeks of treatment. Patients treated with dapagliflozin had a significant, clinically meaningful improvement in the 6-minute walking test distance. The magnitude of these benefits was statistically and clinically significant, spanning all subgroups categorized. This included patients with and without type 2 diabetes and those with an ejection fraction above or below 60%.Anecdote:During a previous clinical rotation, I had a patient taking Jardiance for heart failure. He also had a history of chronic kidney disease and managed his condition well with medications and regular follow-ups. Interestingly, he was prescribed Jardiance®, which I initially believed was solely for diabetes management. When I asked him about it, he explained that his cardiologist prescribed Jardiance specifically for his heart. At the time, I did not understand the rationale behind prescribing Jardiance®, especially since the patient did not have type 2 diabetes. But after researching the medication, I figured that his cardiologist had chosen Jardiance® due to its demonstrated benefits in reducing the risk of cardiovascular death and hospitalization for heart failure. Although initially considered to be only glucose-lowering agents, the effects of SGLT2 inhibitors have expanded far beyond that. Their use has expanded to include heart failure and chronic kidney disease, even in patients without diabetes. It is, therefore, essential that cardiologists, diabetologists, nephrologists, and primary care physicians are familiar with this drug class.Adverse effects:It is worthwhile to note that SGLT2 inhibitors are not typically used as first-line treatment for heart failure, and not all patients with heart failure are appropriate candidates for these medications. SGLT2 inhibitors are generally well-tolerated, but they can cause adverse effects. Genital and urinary tract infections and euglycemic diabetic ketoacidosis are the most common side effects experienced by patients. The incidence of these adverse effects is generally low and can be managed with appropriate monitoring and treatment. In addition, SGLT2 inhibitors can also cause dehydration, electrolyte imbalances, hypotension, and acute kidney injury (AKI). These imbalances are more common in elderly patients or those with renal impairment, like the patient I discussed earlier. Genital yeast infections: Diabetes is also a risk factor for genital yeast infections because glucose in the urine is used as a substrate by microorganisms to grow in the GU tract. UTI and genital yeast infections are prevented by staying well hydrated while taking these meds. Increased intake of water will dilute the urine and decrease the concentration of glucose in urine. UTI/genital yeast infections are treated as usual, and the SGLT-2 can be resumed after infections are treated. In case of recurrence, the clinician may consider discontinuation of medication based on a case-by-case assessment. Patients using SGLT2 inhibitors for treatment should have regular follow-ups with their physicians for the early detection of adverse effects. Bladder cancer: It is not clear if chronic glucosuria is tumorigenic since there are no long-term data. In clinical trials, 10 cases of bladder cancer were diagnosed among dapagliflozin users, five of which occurred only in the first six months of treatment. The FDA has recommended postmarketing surveillance studies. Dapagliflozin is not recommended in patients with active bladder cancer. Bone fractures and limb amputation: One trial (CANVAS) demonstrated an increased incidence of bone fractures and limb amputations among users of canagliflozin, but another trial (CREDENCE) did not demonstrate such an increased incidence of bone fractures or limb amputations. This increased risk has not been proven with empagliflozin. Summary: SGLT2 inhibitors have shown promise in heart failure treatment, particularly in patients with a reduced ejection fraction. Even though the specific mechanism of action through which they work on the cardiovascular system is currently unknown, they have been shown to reduce the risk of hospitalization for heart failure and cardiovascular death in several clinical trials. These medications lower blood glucose levels and have other beneficial effects on the cardiovascular system that make them good options for the management of heart failure.____________________Conclusion: Now we conclude episode number 138, “SGLT-2 inhibitors in heart failure.” Princess explained that SGLT-2 inhibitors have many benefits that go beyond their glucose-lowering properties. Recently, the use of SGLT-2 inhibitors has been extended to include heart failure with reduced ejection fraction and chronic kidney disease, even in patients without diabetes. Dr. Arreaza also explained that FDA has not approved the use of SGLT-2 inhibitors for the treatment of type 1 diabetes because of the reported increased risk of diabetic ketoacidosis or DKA. There is ongoing research about additional uses of SGLT-2 inhibitors, and we are looking forward to hearing more about these medications in the future.This week we thank Hector Arreaza and Princess Enuka. Audio editing by Adrianne Silva.Even without trying, every night, you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you. Send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _________________Links:Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. https://pubmed.ncbi.nlm.nih.gov/32865377/Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. https://pubmed.ncbi.nlm.nih.gov/31497854/Heerspink HJL, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752-772. https://pubmed.ncbi.nlm.nih.gov/27470878/Zelniker TA, Braunwald E. Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(4):422-434. https://pubmed.ncbi.nlm.nih.gov/32000955/Nassif, M. E., et al. (2020). The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial. Nature Medicine, 27(11), 1954-1960. https://doi.org/10.1038/s41591-021-01536-xRoyalty-free music used for this episode: "Tempting Tango." Downloaded on October 13, 2022, from https://www.videvo.net/

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  ‘Teamwork makes the dream work' this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been seen in the announcement of positive trial data for Jardiance, a type 2 diabetes treatment created by an alliance between Boehringer Ingelheim and Eli Lilly, while various research groups team up to bring us closer to a HIV vaccine. 

It's In the News.. a look at the top news stories in the diabetes community over the past seven days. This week, The US FDA gives the green light to Dexcom's G7 CGM, Mark Cuban's Cost Plus Pharmacy puts out a survey all about insulin, new studies looking at teens with type 1 and blood pressure as well as CGM and hospitalizations at the VA and much more! Previous episodes on Dexcom's G7: https://diabetes-connections.com/?s=g7 Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX Our top story is big news.. Dexcom's G7 gets FDA approval. This device with a shorter, half hour warm up time, with the sensor and transmitter all in one piece was approved for people age 2 and up with all types of diabetes. It was approved as an iCGM as expected, which is good news for the automated systems the G6 currently works with.. much more to come of course, we've done a lot of episodes on the features and design of the G7 so I'd urge you to listen to those if you haven't yet and of course we'll follow up with a new episode with Dexcom as soon as they'll talk to me! XX In other news.. Illinois Attorney General files a fraud lawsuit, accusing Eli Lilly, CVS Pharmacy, Novo Nordisk and several other pharmaceutical companies of artificially inflating the cost of insulin by over 1,000% since the late 1990s. The complaint singles out Eli Lilly in particular, noting the price for a dose of its analog insulin Humalog rose by 1,527% between 1997 and 2018. "Remarkably, nothing about these medications has changed," the complaint states. "Today's $350 insulin is the exact same drug defendants originally sold for $20." The suit also notes that 13% of Illinoisans, about 1.3 million people, live with diabetes, making the pharma companies' alleged monopoly scheme a public health threat. There are several other state and class action suits against the insulin makers going through the courts right now. So far none have landed more than a glancing blow. https://www.courthousenews.com/illinois-attorney-general-sues-over-sky-high-insulin-prices/ XX A new contender, though, might be entering the arena. Mark Cuban's Cost Plus Pharmacy put out a tweet this week asking for feedback on adding insulin to their lower-cost inventory. Quote - Insulin users: we are evaluating a future insulin test program and would like your feedback. If we offered a 90-day supply of a fast-acting insulin (up to 12 vials/8 packs of pens) for $170 incl. shipping, what would you think?” There's a feedback form and I'll link that up in the show notes. https://forms.office.com/Pages/ResponsePage.aspx?id=nlWlyavTPES7xglhq5HvDwx1m5bO2mRDq1ekDvUshMtUNUZBM0dDUTA3RVpUOEY1WVNWVDE4U0JTMiQlQCN0PWcu XX People with diabetes who used glucose lowering drugs prior to getting COVID-19 seem to have fewer COVID-19 related adverse outcomes during hospitalization. The mediations have already been shown, albeit in conflicting findings, to have possible benefits regarding morbidity and mortality among patients with diabetes who become infected with COVID-19. These meds include orals like Metformin as well as injectables like sglt2 inhibitors like Jardiance and Invokana GLP-1 agonists like Ozempic and Trulicity. https://www.ajmc.com/view/glucose-lowering-drugs-may-reduce-risk-of-covid-19-related-adverse-events-in-patients-with-diabetes XX New research about opioids and diabetes. This study says people People with diabetes who underwent surgery had a significantly increased rate of prolonged opioid use (POU) compared to people without diabetes who underwent surgery. 56% higher for people with type 2 and more than 200% higher for those with type 1. This was a big, retrospective, observational study of more than 43,000 people who had operations at a single diverse healthcare system in 2008-2019. The researchers say this shows that in a real-world setting healthcare providers are generally not accounting for individual risk factors when prescribing postoperative opioids. https://www.medscape.com/viewarticle/985068 XX Teens with Type 1 diabetes (T1D) who took bromocriptine, a medication used to treat Parkinson's disease and Type 2 diabetes, had lower blood pressure and less stiff arteries after one month of treatment compared to those who did not take the medicine, according to a small study published in Hypertension, an American Heart Association journal. People with type 1 are at higher risk of high blood pressure and those diagnosed with T1D as children have even higher risks for heart disease. Therefore, researchers are interested in ways to slow down the onset of vascular disease in children with T1D. The study's small size is a limitation. However, the researchers note that further research into bromocriptine's impact on vascular health in a greater number of people with Type 1 diabetes is warranted; they are planning larger trials. https://medicalxpress.com/news/2022-12-parkinson-medication-blood-pressure-teens.html XX CVS is facing a fraud charge with a lawsuit accusing them of deceptive fundraising in a campaign it held for the American Diabetes Association. Prior to each customer's transaction, a checkout screen prompts the customer with several options for pre-selected dollar amounts, as well as an opt-out option, allowing donations to the diabetes association. Yet, the plaintiff alleges, CVS did not forward donations to the diabetes association, but instead applied the donations toward a legally binding $10 million obligation CVS made to the diabetes association. In November, Edward L. Powers, a lawyer for CVS, filed a motion to dismiss the case, challenging the plaintiff and his lawyer on their interpretation of the alleged $10 million “debt.” CVS says they agreed to fundraise from customers and turn over the donations to the diabetes association. After more than three years of fundraising, CVS would make up the difference between the cumulative customer donations and $10 million, according to the motion. The group bringing the suit disagrees and says everyone who made a campaign donations” are entitled to damages. https://www.bostonglobe.com/2022/12/05/metro/tweet-draws-attention-lawsuit-accusing-cvs-fundraising-fraud-checkout-cvs-has-filed-motion-dismiss-suit/ XX Wearing a CGM can keep you out of the hospital.. according to a new study focusing on Veterans Affairs clinics in the US. Wearing a CGM was associated with a lower risk for all-cause hospitalization and mortality in adults with type 1 and type 2 diabetes. This was even though the people with type 2 who received CGM were actually unhealthier [than non-CGM users] according to the researchers, who called the mortality reductions, dramatic. During a presentation at the World Congress on Insulin Resistance, this researcher said: “All of this data suggests that we may need to look at these types of outcomes in a much more serious fashion, because there may be some additional benefits that we didn't appreciate. If true, then maybe CGM use may become more like the SGLT2 inhibitors, and we'll start using them in a much more comprehensive way.” https://www.healio.com/news/endocrinology/20221202/cgm-use-lowers-hospitalizations-may-reduce-mortality-in-type-1-and-type-2-diabetes XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX outed by celebrities, raved about by TikTok users, and advertised by med spas, a new class of drugs for treating diabetes and obesity has exploded in popularity for its weight-loss effects, leading to rippling shortages across several of the medications. Amid the surge in demand, Eli Lilly and pharmacies have started to tighten access to the latest of this type of drug, tirzepatide, focusing on giving it to people with type 2 diabetes, the only population it's authorized for so far. But that's left another set of patients scrambling — people with clinical obesity who turned to the medication as one of their few options for treatment. The class of drugs are GLP-1 receptor agonists, which mimic the effects of a hormone that can help people feel full. Within this group, Novo Nordisk's obesity drug Wegovy and diabetes drug Ozempic have been in short supply for months due to manufacturing issues and increased demand. Lilly's diabetes medication Trulicity has also been in tight supply, according to the drugmaker. That leaves tirzepatide, sold under the name Mounjaro. Lilly said in a statement that the drug is currently not in shortage, but that the company is continuing to monitor availability of competitor therapies and “supply with a focus on access for people with type 2 diabetes.” Related: Patients seeking novel weight loss drugs find a ‘wild west' of online prescribers In October, Lilly made changes to a discount program for the drug, now requiring people to attest they have type 2 diabetes. The coupons allowed patients to get the drug for $25 a month when it would otherwise cost about $1,000. Some pharmacies are also now checking if people have a diabetes diagnosis before filling prescriptions. https://www.statnews.com/2022/12/07/eli-lilly-tightens-access-tirzepatide-mounjaro-diabetes-obesity/ XX XX On the podcast next week.. yale lacrosse player Bri Carrasquillo was diagnosed just after her freshman year. Now she's part of Dexcom U – a new program for college athletes with type 1. Last week's show was One Drop is making a CGM? We'll talk to CEO Jeff Dachis about that. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

It's in the News.. the top diabetes stories of the past seven days. This week, one state caps not just insulin prices, but diabetes supplies for some, Lilly is out with a new integrated pen system, new study look at DKA at diagnosis of type 1 and what that means for health issues later on, and more! Learn more about the T1D Exchange: www.t1dexchange.org/stacey  Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM*   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book “Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes” available on Amazon now. XX Delaware Governor John Carney last month signed Senate Bill 316, which will cap the monthly cost of diabetes supplies and equipment at $35 for those on state insurance plans. This law will make blood glucose meters and strips, urine testing strips, syringes, continuous glucose monitors (CGM) and supplies, and insulin pump, and pump supplies more affordable and accessible. Senate Bill 316 will apply to state-regulated health plans and state employee plans, which will take effect in 2023 and 2024, respectively. The $35 per month cap includes deductible payments and cost-sharing amounts charged once a deductible is met. The cap does not, however, apply to high deductible health plans or catastrophic health plans. Although much of the conversation about diabetes costs focuses on insulin, diabetes supplies are also a significant cost for people with diabetes. According to the American Diabetes Association (ADA), people with diabetes have medical expenses of about 2.3 times higher than those without diabetes. Diabetes supplies account for about 15 percent of diabetes medical expenses. On average, people with diabetes, even those with private insurance, spend $490 out-of-pocket on diabetes-related supplies each year. https://diatribe.org/delaware-caps-monthly-cost-diabetes-supplies-35 XX New report estimates 1 point 3 million adults with diabetes have rationed their use of insulin within the last year. That's 16.5 percent of everyone who's been prescribed insulin. We told you about this report published last month in the journal Annals of Internal Medicine. It's getting more attention – and it should – as the Washington Post picked it up for a series of reports their doing on health stats. The report attributes the rationing to the cost of the drug and what it describes as “inadequate” insurance coverage. The price of the four most popular types of insulin has tripled in the past decade, according to the American Diabetes Association. https://www.washingtonpost.com/wellness/2022/11/08/diabetes-insulin-rationing/ XX One of the insulin makers will begin rolling out a new diabetes management platform in the next few weeks. Lilly is launching the Tempo platform, which includes prefilled, disposable Tempo Pens for insulin delivery with the compatible TempoSmart mobile app and the Tempo Smart Button, which is designed to track the pens' insulin dosages.The Tempo Smart Button was cleared by the FDA in mid-September, Lilly said in this week's announcement. When attached to the top of a Tempo insulin pen, it takes in and stores insulin dosing data, then automatically transfers that information to the TempoSmart app. TempoSmart can connect to a variety of other devices and apps, like Dexcom's continuous glucose monitors and Lilly's own blood glucose monitor, among others, but also from more general health-tracking wearables like those from Fitbit, Garmin, Google and Apple. https://www.fiercebiotech.com/medtech/eli-lilly-lines-launch-diabetes-management-platform-tracks-insulin-pen-use-blood-sugar XX XX New research at Georgia Tech shows promise in beta cell transplantation without having to take additional immunosuppressive drugs. This is cell therapy with a new biomaterial called iTol-100. That's the basis of a new startup called iTolerance. Long way to go here but a lot of promise for many other conditions as well at type 1. This is less cell encapsulation, as other companies are working toward, but it's more of a soft material that can mix right with the cells at the time of transplant. This research started with a three year grant from JDRF. https://www.research.gatech.edu/new-startup-develops-potential-cure-type-1-diabetes XX Not a big surprise, but children diagnosed while in DKA can increase the risk of health issues later on. These issues can include extended stays in hospital, poorer long-term control of blood sugar levels, and even a higher mortality rate. The authors of the study point out that providing a comprehensive explanation of the classic symptoms of T1D in childhood to the general public, those active in the childcare or daycare settings, and primary care physicians could help raise awareness of the symptoms of T1D. Furthermore, public health measures could be used, e.g., implementing a general islet-cell autoantibodies screening program for children to reduce the number of dangerous metabolic imbalances. https://www.news-medical.net/news/20221108/Study-highlights-the-need-for-early-and-timely-diagnosis-of-type-1-diabetes-in-children-and-adolescents.aspx XX New weekly injection for type 2 had some promising results, helping people meet blood glucose goals 4-12 weeks earlier than those taking traditional medications. The new medication is called Tirzepatide brand name Mounjaro, and it helped people meet weight loss and blood glucose targets four weeks sooner than semaglutide, which is branded as Ozempic or Wegovy and between four and 12 weeks thatn those treated with once daily long acting insulin like Tresiba. https://scitechdaily.com/a-new-and-improved-diabetes-drug/ XX Quick clarification from last week! I mentioned a study showing that people with type 1 see good results from taking GLP-1 receptor agonists and SGLT 2 inhibitors, two types of drugs approved for type 2. I had said that both also increased the risk of DKA. That's not true.. I got it wrong. Only SGLT 2 inhibitors seem to increase that risk. The GLP-1 medicines have brand names like Ozempic or Trulicity and the SGLT-2 are Invokana or Jardiance. https://www.medwirenews.com/diabetes/real-world-adjunctive-medication-outcomes-type-1-diabetes/23662504 XX XX XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX XX XX On the podcast next week.. Tom from Type One Talks The past episode was all about thinking through your use of CGM, questions to ask of yourself, your family and anyone with whom you plan to share. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

It's in the News.. the top diabetes stories of the past seven days. This week: new research looks at off-label use of GLP and SGLT drugs for people with type 1, Medtronic gets 780G approval in Canada, finger prick early detection of type 1, and lots going on for Diabetes Awareness Month. Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX And by my new book “Still The World's Worst Diabetes Mom: More Real Life Stories of Parenting a Child With Type 1 Diabetes” available on Amazon now. XX Our top story this week, Researchers say a blood test for early diagnosis of type 1 diabetes can stave off serious illness and hospitalization in children. This Australian study looked at the finger prick sample that is collected in the home and mailed to the lab. It included more than 17-thousand children and young adults, mostly in families with a history of type 1. The team of researchers are the first to use this method to screen diabetes in Australia. They said, We want to make type 1 diabetes screening accessible to every Australian child no matter where they live. Our recent work has proven that we can do this cheaply, accurately, and conveniently," The study is published in Pediatric Diabetes. https://medicalxpress.com/news/2022-11-home-screening-diabetes.html XX Medtronic gets the okay from Canada for it's MiniMed 780G system. It's now available in more than 60 countries around the world, with the U.S. notably missing from the list. Current 770G users will be able to upgrade their devices with the new system's software. The MiniMed 780G is equipped with Medtronic's SmartGuard technology, a hybrid closed-loop system what works with Medronic's CGM. It's approved for ages 7-80. Medtnoic submitted to the FDA in the spring of 2021, nearly a year after securing CE mark approval in Europe. The U.S. sign-off has been slow to arrive, however, thanks in large part to the FDA's discovery of quality control issues at the California headquarters of Medtronic's diabetes business. A December 2021 letter from the agency outlined shortfalls it discovered at the Los Angeles-area facility in a routine inspection, prompting Medtronic to implement corrective actions and other process improvements to address the issues. https://www.fiercebiotech.com/medtech/still-awaiting-us-approval-medtronics-auto-adjusting-insulin-pump-lands-canadian-nod XX XX People with type 1 diabetes who take GLP-1 receptor agonists or SGLT-2 inhibitors in real life seem to line up with controlled trials. The GLP-1 medicines have brand names like Ozempic or Trulicity and the SGLT-2 are Invokana or Jardiance. These are newer medications and people with type 1 are cautioned to take them carefully because of the higher risk of DKA. However, these researchers say after 12 months of use people taking a GLP-1 receptor agonist had a significant reduction in glycated hemoglobin (HbA1c), from an average of 7.7% to 7.3% (61 to 56 mmol/mol), as well as in bodyweight, from an average of 90.4 to 85.4 kg. and they used less insulin overall. SGLT2 inhibitors were used by 39 study participants for an average duration of 24.2 months, mostly with the intent to achieve better glycemic control (73.3%), but also for weight loss (37.8%), reduced insulin requirements (26.7%), and reduced glucose variability (24.4%). Also, about 12% of users initiated SGLT2 inhibitors for their beneficial cardiovascular or renal properties. In line with clinical trial findings, these real-world users had significant reductions in average HbA1c after 12 months of use, from 7.9% to 7.3% (63 to 56 mmol/mol), and in basal insulin dose, from a daily average of 31.3 to 25.6 units, but not in bolus insulin. And contrary to the results of controlled trials, although SGLT2 inhibitor users had a weight reduction, this was small and not statistically significant, at an average of 89.2 and 87.5 kg before and after 12 months, respectively. https://www.medwirenews.com/diabetes/real-world-adjunctive-medication-outcomes-type-1-diabetes/23662504 XX Taking a personalized approach to kidney disease screening for people with type 1 diabetes (T1D) may reduce the time that chronic kidney disease (CKD) goes undetected. The finding, published in Diabetes Care(link is external), provides the basis for the first evidence-based kidney screening model for people with T1D. Current CKD screening recommendations include annual urinary albumin excretion rate (AER) testing for anyone who has had T1D for at least five years. The new findings suggest that AER screening could be personalized to optimize testing frequency and early detection of CKD. Specifically, people with T1D who are at low risk of developing CKD could be tested for AER less frequently to reduce burden and cost, and those at high risk for CKD could be tested more frequently to facilitate earlier CKD detection. People with T1D have an estimated 50% risk of developing CKD over their lifetime. Important to note, these numbers and this study is based on 30 years of data, dating back to the landmark DCCT trial. https://www.nih.gov/news-events/news-releases/nih-funded-study-finds-personalized-kidney-screening-people-type-1-diabetes-could-reduce-costs-detect-disease-earlier XX Lots of stuff happening for diabetes awareness month. Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced it will ring the opening bell at Nasdaq on November 1, 2022, in recognition of National Diabetes Awareness Month. “We are proud to celebrate this year's Diabetes Awareness Month by ringing the Nasdaq Opening Bell with representatives of several organizations that make diabetes, and supporting the people who are living with diabetes, their sole focus,” said Devdatt “Dev” Kurdikar, president and chief executive officer of embecta. “Our company is honored to recognize the patients, caregivers, healthcare providers, and advocacy organizations working together to improve access to education and progress toward the vision of a life unlimited by diabetes.” embecta also recognizes the 100-year milestone of the first successful injection of insulin that was administered to a person with diabetes. Today, 1 in 10 adults around the world live with diabetes1, an estimated 537 million people, and almost half don't know they have it. “Our community often faces stigma and isolation associated with diabetes as we frequently practice self-management of the disease,” said Anna Norton, chief executive officer of DiabetesSisters. “Increased access to education and resources that will improve the standard of care and quality of life across the community is essential, and we're proud to stand with embecta to share in this mission.” The bell ringing ceremony will be streamed live via Nasdaq's Facebook page. Additionally, highlights from the ceremony will be shared across embecta's social media channels. Please visit embecta.com for additional information regarding Diabetes Awareness Month. About embecta embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit embecta.com. XX Dexcom has teamed up with ESPN's Adam Schefter – his wife has type 1 – to launch Dexcom U, the first-ever NIL (name, image, likeness) program designed to celebrate college athletes with diabetes and inspire people with diabetes who have athletic dreams of their own. NIL is name image likeness, it's the new program that allows college athetes to be paid. Dexcom says According to a recent study, nearly half (43%) of adults with Type 1 diabetes felt like quitting sports and physical activities because of their diagnosis, and one in five (20%) went through with quitting. These athletes tell their stories and how Dexcom helps them. I'll link up the video and we are set to speak with some of them in the next couple of weeks. XX A new study released by the American Diabetes Association® (ADA), illustrates the significant barriers that low-income Americans, people of color, older Americans, and people with diabetes living in states with the highest prevalence of the disease face in accessing continuous glucose monitors (CGM). These barriers are especially high for Americans on Medicaid, who are the least likely to have access to a CGM. CGMs continually monitor blood glucose (blood sugar), giving real-time updates. The devices provide significant, potentially life-changing benefits for diabetes management, and in turn for the avoidance or delay of serious co-morbidities, hospitalizations, and even death. “It is disappointing to see that access to vital diabetes management tools like CGMs often depends on your income, the color of your skin, your age, and where you live,” said Dr. Robert Gabbay, chief scientific and medical officer at the ADA. "The ADA is committed to addressing access barriers—such as inadequate health insurance coverage, steep Medicare and Medicaid coverage requirements, and physician shortages—to ensure that everyone who can benefit from a CGM can get one.” The ADA is working with the Centers for Medicare and Medicaid Services, state Medicaid programs, and Congress to eliminate barriers people face in accessing diabetes technology like CGMs. The CGM study is available on the ADA's website. XX Diabetes on Nasdaq XX Great start to a blog post by Tim Street, he writes over at DiabeticTech. He's trying out 6 CGMs currently on the market. Dexcom ONE Medtrum Nano Dexcom G6 Glucomen Day GlucoRX Aidex Freestyle Libre2 You can check out his blog to see the photos of him wearing all of the CGMs and hear his methods for testing. https://www.diabettech.com/cgm/unboxing-and-applying-the-six-cgms/?utm_source=dlvr.it&utm_medium=facebook XX Dexcom also has a See Diabetes campaign for this month which gives you a chance to create your own overlay patch. I've created one for the show, you can it on social along with others with the #SeeDiabetes hashtag. Patti LaBelle, Mark Andrews and Nick Jonas are taking part.. If you design an overlay – I'll put the link in the show notes – you may be order a few for free – they're saying limited supply. A cynic would say this is a creative way to use up the G6 overlay patches before the G7 comes out but.. personally I think it's a really creative and fun idea. I like how mu patch came out, but I doubt my son will wear it! XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX XX XX On the podcast next week.. Tom from Type One Talks The past episode was all about thinking through your use of CGM, questions to ask of yourself, your family and anyone with whom you plan to share. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

What do humans and cars have in common? No this is not the start of a lame joke, but it is an introduction to the Diabetes Warranty Program. Similar to your car, which comes with a warranty manual explaining when to take the car in for regular maintenance checks, Dr. E created the Diabetes Warranty Program to prevent, detect, and treat the complications related to diabetes as soon as possible. Learn when you should see your healthcare provider to keep your eyes, kidneys, feet, heart, and mouth running as smooth as your car—or at least as smooth as you'd like your car to run.  Questions We'll Cover in This Episode:·       What is the Diabetes Warranty Program?·       What are the goals of the Diabetes Warranty Program?·       What are the medical recommendations for eye care for people with diabetes?·       What are the medical recommendations for kidney care for people with diabetes?·       What is the recommended blood pressure level for people with diabetes?·       What are the medical recommendations for foot care for people with diabetes?·       What are the medical recommendations for heart care for people with diabetes?·       What are the medical recommendations for oral care for people with diabetes?Show notesTCOYD live kidney care: https://youtu.be/F--YwkaJlToSGLT2 inhibitors: Jardiance, Invokana, Farxiga, SteglatroGLP-1 receptor agonists: Bydureon, Trulicity, Ozempic, Victoza, Adlyxin, Rybelsus Nutrition Videos for Type 1s: https://tcoyd.org/vv-t1d-nutrition/Nutrition Videos for Type 2s: https://tcoyd.org/vv-t2d-nutrition/Exercise Videos for Type 1s: https://tcoyd.org/vv-t1d-exercise/Exercise Videos for Type 2s: https://tcoyd.org/vv-t2d-exercise/ ★ Support this podcast ★

What do you need to know about a once-daily GLP-1 RA and what can you do to help your patients taking this T2D therapy? Join this multidisciplinary discussion with Jim Gavin, MD; Curtis Triplitt, PharmD; and Jeffrey Unger, MD, as they review the mechanism of action, dosing, efficacy, and safety of a once-daily GLP-1 RA for adult patients with T2D.  This program is intended for clinicians. The information presented is aligned with the views and opinions of the speakers and is sponsored by Novo Nordisk. This podcast is not to be used as medical advice and is intended for educational purposes only.Faculty Presenters:James R. Gavin III, MD, PhDClinical Professor of Medicine, Emory UniversityChief Medical Officer, Healing Our Village, Inc.Atlanta, GeorgiaJeff Unger, MD, FAAFP, FACEDiplomate, American Board of Family PracticeAssistant Clinical Professor of Family Medicine, UC Riverside School of MedicineRiverside, CaliforniaDirector, Unger Concierge Primary Care Medical GroupRancho Cucamonga, CaliforniaCurtis L. Triplitt, PharmD, CDCES, FADCESClinical Associate Professor of Medicine Division of DiabetesUniversity of Texas Health at San AntonioTexas Diabetes Institute, part of the University Health SystemSan Antonio, Texas 

The daughter of a father who was a comedian from whom she gained her comedic taste and skill, Lisa became a singer, dancer and model, which still continues to this day, attended North Carolina School of the Arts and University of Cincinnati College Conservatory of Music. She then studied acting and sang under the tutelage of several coaches and teachers in New York and California. Prior to this, at the age of 16, Lisa's first professional gig was as a singer/dancer in 'Hooray for Hollywood' for Carowinds Theme Park, Charlotte, NC, performing 5 shows a day, 6 days a week, later performing on cruise ships and at weddings, bar mitzvas, birthday parties, jingles. As a model she worked on print commercials, hosted shows and television commercials where she can presently be seen on national commercials, such as Jardiance. As an actor, she worked on television shows such as: 'As The World Turns' and 'All My Children', then she became the owner of Actors Connection, which connected actors/artists to agents/directors and other industry guests, specializing in helping actors obtain agency and/or talent manager representation. Lisa created her next business 'Act Outside The Box' as a double entendre coaching and consulting company in 2009, to empower actors who want to build their careers, to the uninitiated or those starting out in the industry. She also wrote a book '8 Steps to Reps' which serves as a pathway to gaining representation in the quickest way. Check out what Lisa offers at: https://www.actoutsidethebox.com and at: https://www.facebook.com/HowtoGetanAgent/ ........... Follow her: @thelisagold and Twitter: LisaGold --- Support this podcast: https://anchor.fm/ozzie-stewart/support

Episode 2059 - On this Monday show, Anna Vocino and Vinnie Tortorich talk cigarettes and TV ads, cholesterol misinformation, drug lies, crazy side effects, and more. https://vinnietortorich.com/2022/03/tv-ads-drug-lies-episode-2059 PLEASE SUPPORT OUR SPONSORS TV ADS Sometimes Vinnie's Hulu movies have ads. This is really the only time he gets to see TV ads. Vinnie thinks of cigarette ads in the 20th century. Doctors were smoking. Nowadays, they can't actually drink in beer ads and everything comes with a warning. But it's not all good news. They would say in these ads that smoking 'makes the air softer.' They'd even show women with black eyes in the ads. But now, we see lots of ads for drugs that people do not need. CHOLESTEROL LIES Now ads largely focus on selling drugs. Vinnie plays a lipitor ad. Companies need folks to stay sick to sell more drugs. Of course, talk to your doctor. But take these ads with a grain of salt -- at best. Vinnie thinks that many of the things these drugs say they will treat may be treated better with diet -- but he is not a doctor, so consult with yours. Never forget: ads used to tell us that cigarettes were healthy. Ads don't always speak the truth. Vinnie hears misinformation about cholesterol all of the time. Doctors are spewing one thing on a commercial and another on Youtube or in the office. Vinnie would advise that you don't go to a GP for cholesterol- and heart-related questions. These drug companies also make taking the drug look attractive. The ads tell you subliminally to get on the drug ASAP. Think of the Jardiance ad. Vinnie and Anna look at the numbers and they show that these drugs don't often work. KETOCON 2022 Vinnie and Anna will be there this year! It takes place July 8 to July 10 in Austin, TX. Get your tickets now!  We'll talk about this more soon. PURCHASE BEYOND IMPOSSIBLE The documentary launched this week on January 11! Order it TODAY! This is Vinnie's third documentary in just over three years. Get it now on Apple TV (iTunes) and/or Amazon Video! Link to the film on Apple TV (iTunes):  Share this link with friends, too! Link to the film on Amazon Video: It's also now available on Amazon (USA only for now)!  Visit my new Documentaries HQ to find my films everywhere: REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere: Please share my fact-based, health-focused documentary series with your friends and family. The more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere: Please share my fact-based, health-focused documentary series with your friends and family. The more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter!

This week on Pharm5: Jardiance indicated for heart failure Drug prices in the SOTU address Vonjo approved for cytopenic myelofibrosis One Male Condom marketed for anal intercourse ASHP Phase I rank list due 11:59 PM Connect with us! Listen to our podcast: Pharm5 Watch us on TikTok: @LizHearnPharmD Follow us on Twitter: @LizHearnPharmD Thank you to Abigail Hulsizer, PharmD, BCPS and student pharmacist Kristopher S. Ingram for your contributions to this episode! References: FDA Approves Treatment for Wider Range of Patients with Heart Failure https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-wider-range-patients-heart-failure. Published February 24, 2022. Accessed February 24, 2022. Jardiance.com. https://www.jardiance.com/heart-failure/. Accessed March 3, 2022. O'Brien S. Biden renews call to let Medicare negotiate drug prices, an effort that has stalled in Congress. CNBC. https://www.cnbc.com/2022/03/02/biden-renews-call-to-let-medicare-negotiate-drug-prices.html. Published March 2, 2022. Accessed March 3, 2022. Dunleavy K. A year later at the SOTU, Deja Vu all over again as Biden calls for lower drug prices, zeroing in on Insulin. Fierce Pharma. https://www.fiercepharma.com/pharma/year-later-sotu-deja-vu-all-over-again-biden-calls-lower-drug-prices-zeroing-insulin. Published March 2, 2022. Accessed March 3, 2022. FDA Approves Pacritinib for Myelofibrosis and Thrombocytopenia https://www.pharmacytimes.com/view/fda-approves-pacritinib-for-myelofibrosis-and-thrombocytopenia. Published March 1, 2022. Accessed March 2, 2022. FDA Permits Marketing of First Condom Specifically Indicated for Anal Intercourse. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-condom-specifically-indicated-anal-intercourse. Published February 23, 2022. Accessed February 24, 2022. Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published January 6, 2022. Accessed March 3, 2022. Summary Results of the Phase I Match for Positions Beginning in 2021. American Society of Health-System Pharmacists Resident Matching Program. https://natmatch.com/ashprmp/stats/2021applstats-ph1.pdf. Accessed March 3, 2022.

It's "In the News..." the only diabetes newscast. This week we find out about: SGLT2 inhibitors, more evidence this T2D med works for T1D, Tandem & Insulet earning calls: what you need to know, Which kids with T1D did even better during COVID? How you sleep could increase risk of gestational diabetes, what's going on for Diabetes Awareness Month and lots more! Have 5 minutes? Give it a listen! -- Join us LIVE every Wednesday at 4:30pm EDT Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android Episode transcription below:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. As always, I'm going to link up my sources in the Facebook comments – where we are live – we are also Live on YouTube and in the show notes at d-c dot com when this airs as a podcast.. XX In the News is brought to you by The World's Worst Diabetes Mom, Real life stories of raising a child with diabetes. Available in paperback, on Kindle or as an audio book – all at Amazon.com -- XX Our top story, evidence that SGLT-2 inhibitors can help kidney and heart health in people with type 1. These are diabetes drugs that are already shown to lower blood sugar levels – they have brand names like Invokana and Jardiance – but they are not approved for T1D in the United States. The problem is that they can lead to DKA even with normal glucose levels. However, they are approved in Europe and many advocates say they can be used safely if people no to monitor closely. https://www.news-medical.net/news/20211107/Study-examines-benefits-of-SGLT2-inhibitors-in-individuals-with-type-1-diabetes.aspx XX Some tidbits in Tandem's third quarter investment call last week. CEO John Sheridan says they plan to ask the US FDA this year to approve Control IQ down to age 2 – right now it's only approved to age six. Also asking for expanded labeling for people with type 2. Mobile bolus or bolus by phone still out there waiting for approval – Sheridan says the FDA last asked them any questions in August. He says they have three initiatives for 2022: filing for the Tsport pump, integrating the upcoming Dexcom G7 and moving ahead with their partnership with Abbott's Libre. Sheridan thinks it'll be a matter of a few months before Tandem pumps integrate the G7 saying, “When it comes to Dexcom, we've integrated three generations of their sensors already. We're on the fourth. We know how to do this” I hadn't heard this, but Sheridan says the Libre had a bit of a hiccup with the FDA approving it as an iCGM, that's a newer designation… because taking vitamin C can throw the readings off.. but he believes they've addressed that. We'll follow up. https://www.fool.com/earnings/call-transcripts/2021/11/03/tandem-diabetes-care-inc-tndm-q3-2021-earnings-cal/ XX Insulet also had their quarterly call – CEO Shacey Petrovic says she's still optimistic about Omnipod 5 being approved this year.. she says they've had a lot of back and forth with the FDA in the last few months and that's what makes her more confident. Other tidbits.. Omnipod reports that 80% of their customers were previously on multiple daily injections only .. no prior pump experience. They think when Omnipod 5 comes out there will be more competitive switchers from other pumps. They reiterated that it will be a limited release when approval comes with a gradual rollout in the US. https://www.fool.com/earnings/call-transcripts/2021/11/04/insulet-corporation-podd-q3-2021-earnings-call-tra/ XX Really interesting news about some children in the US with type 1 during the pandemic – they had more time in range and lower A1Cs during the first year of the pandemic compared to the year before.  They also saw their doctors more, even though 90-percents of the visits were virtual. This was a group of kids ages 1-17 all of whom use a CGM. The researchers say they want to take a closer look to try to figure out why this was the case: speculation ranges from more oversight from parents to flexibility in schedules. I can say this definitely happened in my house.. however I'll also throw in that my son started on his first hybrid closed loop system in Jan 2020 just before the pandemic– Tandem's CIQ - and that made a huge difference, especially when we were stuck at home and he was eating at 2am. They don't mention the insulin delivery system here.. just that every kid had a CGM. https://www.healio.com/news/endocrinology/20211108/metrics-improve-for-us-children-with-type-1-diabetes-using-cgm-in-first-year-of-covid19 XX Something called sleep-disordered breathing may play a role in gestational diabetes and insulin resistance. There isn't a lot of research here.. This study looked at women who had risk factors for obstructive sleep apnea, a form of sleep disordered breathing that has been linked with high blood pressure, heart disease, and Alzheimers. The data suggests those with it may enter pregnancy at higher risk for gestational diabetes and recommend more screening. They added further investigation is needed to see if treating the breathing issue in early pregnancy could improve glucose levels. https://www.contemporaryobgyn.net/view/women-with-sleep-disordered-breathing-linked-to-insulin-resistance-and-gestational-diabetes-risk XX Fun story in football this week: Mark Andrews and Blake Ferguson will face each other in the big Thursday night NFL game. Andrews is with the Baltimore Ravens, Ferguson plays for the Miami Dolphins. They both live with type 1.  It's thought this is the first time two NFL players with T1D have faced each other. They each use Tandem pumps, btw, so expect to see some posts from that company promoting the game. XX Big grant for Beyond Type 1's DKA Awareness Campaign. The Helmsley Charitable Trust is giving them more than $300-thousand dollars for their grassroots messaging movement. This provides posters to schools and communities and sends literature to pediatricians. Almost 50%  patients under the age of 18 in the U.S. are in DKA when diagnosed with Type 1. https://beyondtype1.org/beyond-type-1-receives-300985-helmsley-charitable-trust-grant-for-dka-awareness-campaign/ XX Lots of good stuff happening for Diabetes Awareness Month.. Dexcom is partnering with Nick Jonas and Patti LaBelle… they say to help the diabetes community feel seen and heard, while  advocating for improved access to diabetes care. Nick Jonas has been sharing people living with diabetes on Instagram and that's been really fun to see. Patti LaBelle lives with type 2.  She spoke to Congress earlier this month to talk about better access for people with Type 2 diabetes, especially in communities of color. XX Great round up of this kind of stuff – what the big organizations are doing for Diabetes Awareness Month over at Diabetes Mine.. I'll link that up in the show notes; https://www.healthline.com/diabetesmine/diabetes-awareness-month-2021#dexcom XX quick reminder that the podcast this week is our first ever tech roundtable. Really great discussion with two guys who follow this stuff very closely – Kamil Armacki better known as Nerdabetic and Chris Wilson. We go through everything in front of the USA FDA, some stuff that's approved in Europe and talk about what's coming next. you can listen to wherever you get your podcasts or if you're listening to this as on a podcast app, just go back an episode. Next week: holiday help – ask the Dmoms is back to help you through what can be a stressful time of year. That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.  

Boehringer Ingelheim India Chief On Strategy, Jardiance Challenge, Gender Balance In Pharma by Informa

Top stories this week include: a new adjunct therapy is being tested for type 1, Dexcom and Garmin will officially work together (no more DIY needed), once weekly basal insulin study, can psychedelic drugs prevent type 2?! and Australia bets on Rugby for diabetes education Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here ----- Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners! ----- Get the App and listen to Diabetes Connections wherever you go! Click here for iPhone      Click here for Android Episode transcription below:  Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and I am on location this week. I'm at the She Podcasts LIVE conference.. but the news doesn't wait. So.. these are the top diabetes stories and headlines of the past seven days. As always, I'm going to link up my sources in the Facebook comments – where we are live – and in the show notes at d-c dot com when this airs as a podcast.. so you can read more if you want, on your own schedule. XX In the News is brought to you by Real Good Foods! Find their breakfast line and all of their great products in your local grocery store, Target or Costco. XX Our top story.. There's a lot of buzz these days around adjunct therapy for diabetes.. basically another treatment along with insulin. Earlier this year, a drug so far just named TTP-399 got FDA breakthrough therapy approval. A new study shows it works well to keep people with type 1 out of DKA. This was small study, 23 people. They found that TTP-399 can help lower blood glucose without increasing the risk of DKA. It's important because other adjunct therapy.. such as S-G-L-T-2 inhibitors do help lower blood glucose, but the FDA has said they cause too much of a risk of DKA in people with type 1. Those are brand names like Invokana and Jardiance. Pivotal trials of TTP-399 begin later this year. https://www.biospace.com/article/vtv-therapeutics-type-1-diabetes-drug-shows-promise/ XX New partnership announced today - Dexcom and Garmin. You will still need your phone.. I knew you were going to ask.. but with the new Dexcom Connect IQ apps you can now see your Dexcom G6 info on your compatible Garmin smartwatch or cycling computer. Jake Leach, chief technology officer at Dexcom says.. Garmin is the first partner to connect through the real-time API, which we told you about a few months back. Basically, you'll be seeing more connectivity without having to use a third party, community sourced work around which a lot of people do now. The name here is interesting, right? Connect IQ, very similar to Tandem's Control IQ. But since Dexcom owns a bit of Tandem, maybe that's no coincidence. I've requested an interview with Dexcom so maybe we'll find out. garmin.com/newsroom, email media.relations@garmin.com, or follow us at facebook.com/garmin, twitter.com/garminnews, instagram.com/garmin, youtube.com/garmin or linkedin.com/company/garmin. XX New study about time in range, hybrid closed loop systems and faster insulins. The headline here is that using Fiasp with the Medtronic 670g system resulted in greater time in range. How much? The Fiasp group spend 82 point 3 percent time in range.. the Novolog group spent 79.6 percent time in range. This was over 17 weeks and the participants mostly bolused AT meal times, not before, no prebolusing. The researchers echo what I was going to say here, quote – “While the primary outcome demonstrated statistical significance, the clinical impact may be small, given an overall difference in time in range of 1.9%.” So just a heads up if you see headlines screaming about how much faster Fiasp is because of this study. https://www.endocrinologyadvisor.com/home/topics/diabetes/type-1-diabetes/fast-acting-insulin-aspart-versus-insulin-aspart-closed-loop-type-1-diabetes/ XX People who have tried a psychedelic drug at least once in their lifetime have lower odds of heart disease and diabetes. This is a University of Oxford study published in Scientific Reports. These researchers examined data from more than 375-thousand Americans who had taken part in an annual survey sponsored by the U.S. Department of Health and Human Services. Participants reported whether they had ever used the classic psychedelic substances including LSD, mescaline, peyote or psilocybin. They also reported whether they had been diagnosed with heart disease or diabetes in the past year. The researchers found that the prevalence of both conditions was lower among psychedelic users. While no one is recommending you start taking mushrooms to avoid diabetes.. there's a growing push to start serious research to investigate the link between psychedelics and cardio-metabolic health. https://www.psypost.org/2021/10/psychedelic-use-associated-with-lower-odds-of-heart-disease-and-diabetes-study-finds-61958 XX Update on the once a week basal insulin I've been reporting on for a while.. both Lilly and Novo Nordisk are testing their own version of this.. this most recent study looks at the Lilly version called Tirzepatide. These researchers found it to be safe and effective with lower rates of hypoglycemia and slightly lower A1Cs than daily basals like Lantus or Tresiba. Lots of studies ongoing here, for both brands of potential once a week dosing, including a large phase 2 program that includes people with type 1. https://www.healio.com/news/endocrinology/20211012/novel-onceweekly-basal-insulin-safe-effective-in-type-2-diabetes XX More to come, including how rugby and diabetes education may go together.. But first, I want to tell you about one of our great sponsors who helps make Diabetes Connections possible. Real Good Foods. Where the mission is Be Real Good They make nutritious foods— grain free, high in protein, never added sugar and from real ingredients—we really like their breakfast line.. although Benny rarely eats the waffles or breakfast sandwiches for breakfast.. it's usually after school or late night. Ugh.. do your teens eat breakfast? You can buy Real Good Foods online or find a store near you with their locator right on the website. I'll put a link in the FB comments and as always at d-c dot com. Back to the news… -- Getting out of the doctor's office and into something that people can actually relate to.. Diabetes Australia is using rugby to teach men about the risks of type 2 diabetes. League Fans in Training (League-FIT) is based on a Scottish initiative that used football teams to deliver exercise and nutritional advice to overweight and obese men. The program includes education and goal setting and a rugby league-based exercise session, delivered by coaches and some of the club's players. What I really like about this is that -from what I can tell - they're focusing on small changes and not telling these guys to give up everything they like to eat and drink or that they have to become professional players to get a little bit more fit. Imagine if NFL players had a clinic for fans to come and learn a little bit about fitness and nutrition? Again, not to be pros.. just to live a little better and lower risks of type 2. https://www.diabetesaustralia.com.au/news -- On Diabetes Connections this week, we're talking to a mom with type 1 who has had two children during the pandemic. One last summer and the other just a few days before our interview! That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

"Dagáll læknanemans" er hlaðvarp fyrir læknanema og annað áhugasamt fólk um hvaðeina sem viðkemur klínik og læknisfræði. Stjórnendur eru Sólveig Bjarnadóttir og Teitur Ari Theodórsson. Í þessum þætti er fjallað um lyfjameðferð við sykursýki 2. Mörgum lyfjum er hægt að beita og sífellt bætast fleiri lyf við. Arna Guðmundsdóttir, sérfræðingur í innkirtlalækningum, segir frá hvernig lyfin verka og hvernig hægt er að velja rétta lyfið fyrir hvern og einn sjúkling. Þessi þáttur er sá fyrsti af þremur sem unnir eru í samstarfi við læknadeild. Munu þeir nýtast í kennslu í lyfjafræði á 3. ári við Háskóla Íslands. Magnús Karl Magnússon, prófessor í lyfjafræði og sérfræðingur í blóðlækningum, heldur utan um verkefnið og er jafnframt viðmælandi í þáttunum þremur.  Hér má finna meðferðarskemað sem vísað er í í þættinum:https://drive.google.com/file/d/1w82td61yO6GvW-dnqn_on0CxAow8IaPR/view?usp=sharing Dagáll læknanemans er sjálfstæð þáttasyrpa innan Hlaðvarps Landspítala. Þættirnir eru aðgengilegir á helstu samfélagsmiðlum Landspítala og einnig í streymisveitunum Spotify og Apple iTunes, ásamt hlaðvarpsveitum á borð við Simplecast, Pocket Casts og Podcast Addict.(Tónlist: "Garden Party" með Mezzoforte. Notað með leyfi frá hljómsveitinni.)SIMPLECAST:https://landspitalihladvarp.simplecast.com/episodes/dagall-19

Dans cette 43e baladodiffusion, les Dr Charles Dussault et Luc Lanthier de l'efficacité de l'empagliflozine (Jardiance®), un inhibiteur des SGLT2, chez les sujets avec insuffisance cardiaque à fraction d'éjection préservée avec l'étude EMPEROR-Preserved, en plus de réviser la littérature médicale de juin, juillet et aout 2021.   Quiz clinique (3 min 41), étude principale (4 … Continuer la lecture de « BC 043 – Efficacité de l'empagliflozine chez les sujets avec insuffisance cardiaque à fraction d'éjection préservée (étude EMPEROR-Preserved) »

In this episode editors Michael Flanagan and Simon King the FDA's new safety labelling for JAK inhibitors, impressive new data for Jardiance in heart failure and controversy around COVID-19 booster shots.

This week we have significant news on the status of a third COVID-19 vaccine booster dose, as well as news for an encephalitis vaccine, another jardiance indication, an FDA warning concerning patient wristbands, and Jemperli gets accelerated approval. 

Twelve is a solid number of eps per season YKNOW??????!Plus I do feel we are in a NEW ERA of the show… so it feels right to have a NEW STARTING POINT or sumthin.I KNOW that the Z-word we refer to is ACTUALLY just someone who MAKES the stuff, not necessarily a CONNOISSEUR of the stuff but let's “be real”… if you're gonna make the stuff, you “should” be a CONNOISSEUR of the stuff…. AND VICE VERSA FREAKIN PROBABLY!!!?PS our “editing team” cut out an entire 6+ minutes from this about picking your own line at the grocery store vs getting into a separate pre-line with your fellow shoppers so you all have the best chance of getting the best available line. Ms. F had NO IDEA what I was talking about and it was STUPID… but I'm sure “y'all” would back ME up on that anyway right??????!And I KNOW it's EASY to “make fun of” prescription drug commercials BUT WTF is that side effect for your Type 2 diabetes pill, JARDIANCE®️?????PS I don't think we'll ACTUALLY talk about the Olympics every week bc they're over now (I think?) and we didn't even watch em.MAYBE WE WILL THO!WATER POLO LOOKS LIKE GYM CLASS! Keep listening… TELL YOUR FRIENDS!SEND @MRFITXIT YOUR WINNIFRED CLEO SUBMISSIONS!!!We LOVE YOU!!!C-L-I-T-O-R-iiiii-S….C-L-i-P….P-E-R-S!!!!!!!!!!!!!!!!C-L-I-T-O-R-iiiii-S….C-L-i-P….P-E-R-S!!!!!!!!!!!!!!!!

In this episode, editors Michael Flanagan and Simon King discuss key opinion leader (KOL) feedback on new heart failure data for Eli Lilly and Boehringer Ingelheim's SGLT-2 inhibitor Jardiance, look at Biogen's deal to in-license a Chinese developed BTK inhibitor in early stage testing for multiple sclerosis and talk about Eli Lilly's bid to upgrade first-generation KRAS inhibitors.

FirstWord Pharma PLUS editors Michael Flanagan and Simon King discuss the potential role of Eli Lilly and Boehringer Ingelheim's Jardiance as a future treatment for heart failure, the FDA's decision to narrow labelling for Biogen's Aduhelm, the pending departure of cancer R&D head Axel Hoos from GlaxoSmithKline and whether UCB's bimekizumab can disrupt the psoriasis market.

Prescription medications such as Eliquis, Jardiance, Spiriva, and Tradjenta have gone up 6%. Drugs such as Truvada, Chantix, Flovent, and Premarin have gone up between 3 to 5 percent.https://recoverypartnernetwork.com/drug/how-much-do-drugs-cost-the-steep-price-of-addiction

In this episode, we discuss: What is the non-medication treatment of diabetes? 2:05What are some of the common medications used to treat diabetes? 3:48Does everyone with diabetes need to be on medications? 4:45How do you know if your diabetes is well-controlled? 5:34What is metformin and what are the side effects? 6:11What is Hemoglobin A1C? 7:09What if my blood sugars are still high after starting metformin? 7:26What is emagliflozin (Jardiance), canagliflozin (Invokana), or dapagliflozin (Forxiga)? 8:18What are the side effects of SGLT2 inhibitors? 9:24What is gliclazide (Diamicron)? 9:48What is sitagliptin (Januvia), linagliptin (Trajenta), or saxagliptin (Onglyza)? 10:20What should I do if I'm not feeling well? 11:08What is liraglutide (Victoza), dulaglutide (Trulicity), or semaglutide (Ozempic)? 11:49When do we use insulin? 12:38Are there different kinds of insulin? 13:17What are some examples of different insulin regimens? 14:01What other resources do you recommend? 14:53Diabetes Canada: https://www.diabetes.caAmerican Diabetes Association: https://www.diabetes.orgEmail: thedoctordictionary@gmail.comTwitter: @TheDrDictionaryPeer reviewed by Dr. Rob Silver, Endocrinologist at University Health Network (UHN) in Toronto, CanadaOriginal music by Nicholas and John BragagnoloDISCLAIMER: This podcast isnt meant to be a replacement for a traditional doctor's appointment, nor is it meant to be providing medical advice. Rather, it is meant to supplement your doctor's visit and explain why your doctor asked what they asked, and help explain the diagnosis and common treatment plans.Doctors often have very different styles and approaches to a patient and their diagnosis. If we discuss a question or treatment plan that your doctor didnt mention, that doesn't mean that they are a bad doctor. This could represent a difference in practice style, or the fact that your doctor knows you better than we do, and has created a treatment plan that better fits your lifestyle. In case of emergency, please go to your local emergency department. 

Jörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that GLP-1 receptor agonists like semaglutide and SGLT-2 inhibitors like Jardiance in treating NASH patients.Over the next couple of years, we are likely to see improvements in our ability to diagnose and track NASH patients but no new medicines to treat them. On this podcast, Jörn Schattenberg reviews data on the role that two relatively recent classes of diabetes drugs, GLP-1s (semaglutide) and SGLT-2s (Jardiance), can play in NASH and NAFLD therapy. Wayne Eskridge discusses implications for patients. while Louise Campbell and Roger Green elaborate opportunities and challenges in educating patients and health care professionals to think about liver and diabetes in a more integrated way. This episode presents perspectives and concepts with value today.

This week, the top managed care news included new CDC guidance to base state COVID-19 vaccine supply on administration rates; a report finds record drop in cancer mortality but persistent disparities; Jardiance moves 1 step closer to FDA approval for use in heart failure.

در این اپیزود گفتگو می کنیم با دکتر سعیده فارس پور، متخصص پزشکی خانواده، در مورد بیماری دیابت، انواع و درمان های آن --- « سوالات مطرح شده » علت بروز بیماری دیابت چیست علائم بالینی تیپ ۲ دیابت چیست علاوه بر تست قند خون، چه تست دیگری برای تشخیص و پیگیری دیابت وجود دارد چه درمانهایی برای بیماری دیابت وجود دارد چرا سولفونیل اوره ها در درمان دیابت تیپ ۲ دیگر جایگاهی ندارند داروهای جدید در زمینه درمان دارویی دیابت نقش انسولین در درمان دیابت چیست --- « کلمات کلیدی » HbA1C, Metformin, Glimepirid, SGL2, Jardiance, GLP-1, Victoza, Ozempic, DPP-4 inhibitors, Januvia, DPP4. --- مجری: میترا نادعلی تدوین: امیر ختایی انتخاب موسیقی: کتایون صابری ---

Empagliflozin (Jardiance) reduserer risikoen for kardiovaskulær død og sykehusinnleggelse med 25 prosent hos pasienter med hjertesvikt. Vi oppsummerer Emperor-Reduced studien som ble presentert på den store hjertekongressen European Society of Cardiology (ASC) i dag med kardiologiprofessor Dan Atar. Han tror SGLT2-hemmerne kommer til å bli sentrale i behandlingen av hjertesvikpasienter. See acast.com/privacy for privacy and opt-out information.

Topic: Tips on Traveling with Type 2 Diabetes!Spending some of your holiday season on the road or in the air? This episode highlights ways to prep when traveling with Type 2 Diabetes. Diabetes Dilemmas (Q&A):I answer a Diabetes Dilemma question on insulin timing and Jardiance, a type 2 diabetes medication.Have a Diabetes Dilemma? Ask Me HERE!Or, find me on:Facebook: https://www.facebook.com/Type2andYouwithMeg/Instagram: https://www.instagram.com/type2andyou_by_a_cde/Twitter: https://twitter.com/Type2andYouCDETake Away of The Day:I give recommendations on how to turn today's topic into action. Find additional resources and supportive tools on Type2andYou.Org. Looking for the Frio Pack I mentioned in the episode? Click here!

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast. This week, the top managed care news included President Donald Trump vowing to lower drug prices during his State of the Union address; 3 corporate giants joined forces on healthcare; and CAR T-cell therapy was named the cancer advance of the year. Read more about the stories in this podcast: Trump Targets Drug Prices, Right-to-Try in State of the Union: www.ajmc.com/newsroom/trump-targets-drug-prices-righttotry-in-state-of-the-union CDC Chief Resigns After Trading in Tobacco Stocks: www.ajmc.com/newsroom/cdc-chief-resigns-after-trading-in-tobacco-stocks Amazon, JPMorgan Chase, Berkshire Hathaway: We'll Tackle Employee Health Costs With New Firm: www.ajmc.com/newsroom/amazon-jpmorgan-chase-berkshire-hathaway-well-tackle-employee-health-costs-with-new-firm Prime Therapeutics, Boehringer-Ingelheim Reach Outcomes-Based Contract for Jardiance: www.ajmc.com/newsroom/prime-therapeutics-boehringeringelheim-reach-outcomesbased-contract-for-jardiance CAR T-Cell Therapy Named ASCO's Advance of the Year: www.ajmc.com/newsroom/car-tcell-therapy-named-ascos-advance-of-the-year Evidence-Based Oncology—January 2018: www.ajmc.com/journals/evidence-based-oncology/2018/january-2018

If you are interested in the low-carb, moderate protein, high-fat, ketogenic diet, then this is the podcast for you. We zero in exclusively on all the questions people have about how being in a state of nutritional ketosis and the effects it has on your health. There are a lot of myths about keto floating around out there and our two amazing cohosts are shooting them down one at a time. Keto Talk is cohosted by 10-year veteran health podcaster and international bestselling author Jimmy Moore from “Livin’ La Vida Low-Carb” and Pittsburgh, PA functional medicine practitioner Dr. Will Cole from DrWillCole.com who thoroughly share from their wealth of experience on the ketogenic lifestyle each and every Thursday. We love hearing from our fabulous Ketonian listeners with new questions–send an email to Jimmy at livinlowcarbman@charter.net. And if you’re not already subscribed to the podcast on iTunes and listened to the past episodes, then you can do that and leave a review HERE. Listen in today as Jimmy and Will chew the fat on all of your low-carb, high-fat, ketogenic questions in Episode 86. GET A $39 BOTTLE OF OLIVE OIL FOR JUST A BUCK GET YOUR $39 BOTTLE FOR JUST $1 NOTICE OF DISCLOSURE: Paid sponsorship *****SPECIAL THANKS to Jeffery (Thank you for all the great information that you share. I view you as a "content curator", saving me an enormous amount of time that I would otherwise spend searching through Google and Amazon. A bunch of friends have asked me how I lost 20 lbs in 2 months. I try not to evangelize, but it's hard when I'm so enthusiastic! My knee pain is gone, my blood work has improved, I can think more clearly and more. I hope some of my friends actually get on-board so they can reap benefits for themselves. I do tell them that what works for them may be different from what works for me. I appreciate the scrupulous honesty that is readily apparently in all your podcasts, which is so rarely found across today's social media.), Eulises, and Penny (I've been a listener of your Keto Talk podcast for quite a while now and have experienced an amazing turnaround in my health since starting keto/IF four years ago! After suffering with T2 diabetes for over 16 years following my doctor's pharmaceutical approach and completely wrong nutritional advice, I did my own research and discovered keto. I've now reversed diabetes, lost over 65 pounds and gotten off ALL my prescription meds! I'm 59 years old and in better health and am more fit than I've been in decades. Thanks Jimmy & Dr. Cole for sharing your knowledge and experience. Your podcast is a great motivator for me. Keto On!!)******   Go to PayPal.me/KetoTalk to make a donation.  You can set up automatic monthly payments there BECOME A NUTRITIONAL THERAPY PRACTITIONER Sign up by February 2018 for the 9-month program NOTICE OF DISCLOSURE: Paid sponsorship KEY QUOTE: “Most of the time if someone has a well formulated ketogenic diet, what they think is hunger is just a lingering habit.” — Dr. Will Cole THE PERFECT KETO SUPPLEMENT USE COUPON CODE LLVLC FOR 15% OFF NOTICE OF DISCLOSURE: Paid sponsorship Here’s what Jimmy and Will talked about in Episode 86:   New diabetes drug called Jardiance  – TV AD HOT TOPICS: Snacking on keto Too much fat on a ketogenic diet What are the basic health tests to track while eating low-carb, high-fat? – From fatigue and muscle wastage to total 'brain mush': What REALLY happens when you cut carbohydrates from your diet – Using new study to back high-fat, low-carb diets is flawed logic – New discovery could explain metabolic benefits of low-carb diet – Hurricane Irma may speed the end of orange juice, America’s biggest source of ‘fruit’ MAKE KETO EASIER WITH FBOMB JIMMYLOVESFBOMB FOR 10% OFF YOUR FIRST FOOD ORDER NOTICE OF DISCLOSURE: Paid sponsorship – Why am I experiencing diverticulitis since adopting a ketogenic lifestyle? What can I do to best manage this while remaining keto? Hello Jimmy and Will, I started eating low-carb keto in April this year as a way to lose weight. I have struggled staying in ketosis, but have lost over 20 pounds so far. But my biggest problem is I’ve been having bouts of diverticulitis since making this dietary change forcing me to take Metamucil to raise my fiber intake. My doctor is recommending that I discontinue the ketogenic approach even though he was the one that encouraged me to pursue it in the first place. My C-Reactive Protein is elevated and I am now getting concerned. I’ve done my homework on a ketogenic diet reading all the books and websites and am fully convinced it’s the way to go. I hold a PhD in Biomedical Science from a US medical school and even though all I have read runs counter to what I learned in graduate school, I am fully converted and convinced of keto. Have you run into this problem before? If so, how should I proceed? Rod – STUDY: Dietary Supplement With Ketones May Mitigate Migraine Attacks Join The Keto Clarity Club For $1 Blood Ketone Test Strips!   1. What impact on ketosis will there be with the complete removal of the thyroid? Hi Jimmy and Dr. Cole, I have been eating keto since May 2016 and I feel great! I regularly check my blood ketones and am usually in the 0.7-2.0 range. I was diagnosed with Hashimoto's in 2006 and have been on 100 mcg Synthroid ever since. My thyroid levels were all in range last June but my thyroid kept getting larger. During the summer, my doctor found a nodule that ended up showing Hurthle cells. This concerned my doctor who said it’s a cancer risk and he recommended a total thyroidectomy. My surgery is schedule for next week and I’m wondering what impact this will have on my pursuit of nutritional ketosis. Will this make it more difficult for me to stay in ketosis if I no longer have a thyroid? I just want to know what I’m getting myself into so I can respond accordingly after the surgery. Love your show and keep it up! Liane KEY QUOTE “We shouldn't gorge on any food, whether it's fat, protein, or carbohydrate. Eat to satiety means finding how much is right for you and knowing when to stop.”  – Jimmy Moore 2. Did a ketogenic diet cause a rise in SHBG and a decrease in testosterone levels? What can I do to my keto approach to remedy this? Hey guys, I’m a big fan of Keto Talk and I’ve been eating this way for about a year with great results for the most part. But I noticed a couple of months after starting a ketogenic diet, my sex hormone binding globulin rose from 50 to 70 and my testosterone tanked. I’ve since run these tests several more times and they all confirm the same thing. From what I’ve read, this means my body’s ability to use any available testosterone has been hampered and many sites online blame a low-carb diet as the culprit. I need you to talk me off the ledge on this and help me figure out what is going on. Thanks, Zach 3. Does eating a low-carb, high-fat, ketogenic diet make the urine pH more acidic? If so, should I be worried about this at all? Dear Jimmy and Dr. Will, Yesterday, I went to see my General Practitioner to review my latest bloodwork. She knows I’ve been eating a ketogenic diet for the past nine months and was nothing but pleased with all my markers—except for one. My urine pH was 5.5 and she noted that indicates my body is a bit acidic. She said I shouldn’t worry about this since all the other numbers are perfectly fine, but she made the following statement that stopped me in my tracks: “I am not sure, but maybe it’s the ketones you are excreting that makes your urine more acidic.” What?! Is it true that being in ketosis makes your urine acidic? Should I be worried at all about this or is this of no concern at all. Thank you for your help! Miguel   KETO TALK MAILBOX – If the body prefers to be fueled by ketones, then why does it preferentially burn glucose over fat when both are present? Hello you guys, I am currently reading Keto Clarity and the biggest question I'm having about keto is this: If my body truly prefers being in a state of nutritional ketosis and runs more optimally on ketones than on glucose, then why does my body choose to preferentially choose burning sugar over fat if both are present? I have a fear that years down the line, this whole keto diet will negatively impact my health. Is that fear justified? Thank you, Judy iTunes reviews:   LINKS MENTIONED IN EPISODE 86 – SUPPORT OUR SPONSOR: Join Jimmy Moore’s Keto Support Group: KetoClarityAcademy.com – SUPPORT OUR SPONSOR: Join The Keto Clarity Club For $1 Blood Ketone Test Strips! BestKetoneTest.com – SUPPORT OUR SPONSOR: The world’s freshest and most flavorful artisanal olive oils. Get your $39 bottle for just $1. – SUPPORT OUR SPONSOR: Become A Nutritional Therapy Practitioner – SUPPORT OUR SPONSOR: Jump start your ketogenic diet with PerfectKeto.com/Jimmy (USE PROMO CODE LLVLC FOR 15% OFF) – SUPPORT OUR SPONSOR: Drop an FBOMB for the freshest, high-quality fats from JimmyLovesFBomb.com (Get 10% off your first food order with coupon code “JIMMYLOVESFBOMB”) – From fatigue and muscle wastage to total 'brain mush': What REALLY happens when you cut carbohydrates from your diet – Using new study to back high-fat, low-carb diets is flawed logic – New discovery could explain metabolic benefits of low-carb diet – Hurricane Irma may speed the end of orange juice, America’s biggest source of ‘fruit’ – STUDY: Dietary Supplement With Ketones May Mitigate Migraine Attacks – Jimmy Moore from “Livin’ La Vida Low-Carb” – DR. Will Cole D.C. from DrWillCole.com – HELP KEEP KETO TALK ON THE AIR: MAKE A DONATION HERE

In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.

Today in FirstWord:

In this episode, we discuss newly approved agents for diabetes mellitus: Afrezza (inhaled human insulin), SGLT2 inhibitors (Invokana, Farxiga, Jardiance), and long-acting GLP-1 agonists (Bydureon, Tanzeum).